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ABSTRACT OF THE DISSERTATION 
 Urine Trouble: A Molecular and Anatomical Examination of Bladder Pain 
by 
Lara Wiley Crock 
Doctor of Philosophy in Biology and Biomedical Sciences 
Neurosciences 
Washington University in St. Louis, 2013 
Professor Robert W. Gereau, Chairperson 
Interstitial cystitis or painful bladder syndrome (IC/PBS) is a chronic pain syndrome affecting 3-
6% of women in the US.  Some evidence suggests urothelial injury may cause some cases of 
IC/PBS.  To examine how urothelial injury modulates bladder pain, three injury models were 
used: Infection with uropathogenic Escherichia coli (UPEC, inflammatory), Protamine sulfate (PS, 
non-inflammatory chemical), and lipopolysaccharide (LPS, non-infectious and inflammatory) 
treatment.  Surprisingly, injury with PS decreased, while UPEC alone increased the pain 
response to bladder distention.  These data suggest that changes in the urothelium may 
modulate some forms of IC/PBS.  However, in most cases, patients with IC/PBS have no 
histological abnormalities. Therefore, other molecular mediators may modulate IC/PBS.            
 Glutamate, the major excitatory neurotransmitter in the CNS, modulates a host of 
physiological responses through the actions of ionotropic (iGluRs) and metabotropic receptors 
(mGluRs).  Metabotropic glutamate receptor 5 (mGluR5) has previously been shown to have an 
important role in somatic inflammatory and neuropathic pain models.  However, there is limited 
evidence that mGluR5 in the CNS has a role in bladder pain.  To determine the function of 
mGluR5 in non-inflammatory bladder pain, mice with a targeted genetic deletion of mGluR5 
(mGluR5 KO) were used. Both mGluR5 KO mice and mice given a specific mGluR5 antagonist 
(fenobam) had a reduced bladder pain response.  Systemic treatment with fenobam in mice 
infected with UPEC also resulted in a reduced response to bladder distention.  Thus suggesting 
that mGluR5 is necessary for the full expression of inflammatory and non-inflammatory bladder 
pain.   
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However, these techniques do not indicate the site of action because mGluR5 is 
expressed throughout the pain neuroaxis. Antagonism of mGuR5 in the right central nucleus of 
the amygdala (CeA) is analgesic in a somatic inflammatory injury model.  To examine the role of 
mGluR5 in the CeA, pharmacological activation of Group I mGluRs (mGluR5 and 1) was 
examined.  Activation of mGluR5/1 in the CeA was sufficient to increase the pain response to 
noxious bladder distention.  Additionally, pharmacological inhibition and virally mediated 
conditional deletion of mGluR5 in the CeA reduced the evoked response to bladder distention.  
Finally, optogenetic activation of the CeA increases the pain response to bladder distention 
suggesting that mGluR5 activation increases neuronal excitability in the CeA, increasing 
sensitivity to bladder distention.  Overall, these data suggest a role of urothelial injury and 
mGluR5 in bladder pain. 
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Chapter 1 
Introduction to the Role of Metabotropic Glutamate Receptor 5 (mGluR5) in Bladder Pain 
	   2	  
Pain serves as a vital warning system that protects one’s body from harm.  However, it serves no 
protective purpose if no injury or potential injury has occurred or if pain persists after an injury has 
healed.  Chronic pain is often accompanied by secondary symptoms such as poor quality of life, 
anxiety and depression (Hunt and Mantyh, 2001).  A type of chronic pain that affects 3-6% of 
women in the US is interstitial cystitis/painful bladder syndrome (IC/PBS) (Berry et al., 2011). 
IC/PBS is characterized by: 1. Chronic pelvic pain (>6 months) that is perceived to be related to 
the urinary bladder, 2. at least one other urinary symptom, and 3. the absence of infection or 
other identifiable cause (Theoharides, 2007; Hanno et al., 2010).   Patients suffering from IC/PBS 
have a poor quality of life that is similar to patients in end-stage dialysis (Held PJ, 1990).  In the 
U.S., the annual cost of IC/PBS symptom management exceeds $750 million (Clemens et al., 
2008b; Hanno et al., 2011).  Despite the prevalence and severity of IC/PBS, there have been no 
conclusive advances in understanding the pathogenesis or etiology of the disease (Sand, 2006; 
Clemens et al., 2008a; Hanno et al., 2010). Yet, several hypotheses exist (see etiological schema 
Figure 1.1) (Hanno et al., 2010).  These include, but are not limited to: infection (Domingue et al., 
1995; Duncan and Schaeffer, 1997; Keay et al., 1998; Haarala et al., 1999; Nickel et al., 2010; 
Rudick et al., 2010; Rudick et al., 2011), autoimmunity (Altuntas et al., 2011), alterations of the 
urothelium (Wilson et al., 1995; Hurst et al., 2007; Parsons, 2007; Keay, 2008; Birder, 2011) or 
neurochemical changes in the pain neuroaxis (Aaron and Buchwald, 2001; Aaron et al., 2001; 
Erickson et al., 2001; Brand et al., 2007).  The symptom of bladder pain in IC/PBS has been the 
hypothesized to be the result of urothelial damage leading to neurochemical changes in the spinal 
cord or brain (Parsons, 2007; Keay, 2008; Hanno et al., 2010) (see figure 1.1).  Alternatively, it is 
hypothesized that IC/PBS is part of a larger group of chronic pain syndromes including 
fibromyalgia (Aaron and Buchwald, 2001; Aaron et al., 2001; Erickson et al., 2001; Brand et al., 
2007).  Regardless of the etiology, different types of chronic pain have been shown to produce 
distinct neurochemical changes in the spinal cord and brain (Hunt and Mantyh, 2001).  Several 
recent studies have pointed to the amygdala as an important site in the brain for processing 
painful information(Neugebauer, 2007; Ji and Neugebauer, 2009; Kolber et al., 2010).  
Specifically, the central nucleus of the amygdala (CeA) has been identified as a key structure in 
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the modulation of somatic and visceral pain (Neugebauer et al., 2004; Carrasquillo and Gereau, 
2007; Neugebauer, 2007; Kolber et al., 2010; Gustafsson and Greenwood-Van Meerveld, 2011; 
Myers et al., 2011).  Decoding how injury to the bladder urothelium modulates bladder pain, as 
well as identification of molecular mediators in the pain neuroaxis that modulate bladder pain, 
could provide important molecular targets for new therapies.  One possible molecular target in the 
pain neuroaxis is the metabotropic glutamate receptor 5 (mGluR5). Modulation of this G protein-
coupled transmembrane receptor has shown promise in a variety of somatic inflammatory pain 
models (Varney and Gereau, 2002; Cruz and Cruz, 2007; Montana et al., 2009; Kolber et al., 
2010). Furthermore, recently mGluR5 in the right CeA has been identified as a key modulator of 
somatic inflammatory pain(Ji and Neugebauer, 2009; Kolber et al., 2010).  It is the goal of this 
thesis to examine how distinct urothelial injuries result in bladder pain.  We use three distinct 
models of bladder injury to determine how urothelial injury modulates bladder pain.  Additionally, 
it is the goal of this thesis to examine how an important regulator of other types of pain, mGluR5, 
modulates bladder pain.  In chapter 3 of this thesis, we use genetic and pharmacologic methods 
to examine the role of mGluR5 in both inflammatory and non-inflammatory bladder pain.  In 
chapter 4 of this thesis, we examine how mGluR5 in the CeA modulates bladder pain.    
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Figure 1.1. Proposed etiologic cascade leading to IC/PBS adapted from Figure 2 in (Hanno et al., 
2010) 
Assessment of Bladder Pain In Rodents 
The International Association for the Study of Pain (IASP) defines pain as “an unpleasant sensory 
and emotional experience associated with actual or potential tissue damage, or described in 
terms of such damage.”  While nociception is defined as “The neural process of encoding and 
processing noxious stimuli’ (Loeser and Treede, 2008).  Pain is emotional and subjective while 
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nociception is the sensory process that may or may not be associated with the experience of 
pain.  Peripheral nociception can exist in the absence of pain and vice versa.  For example 
peripheral anesthesia blocks the conscious experience of pain without affecting peripheral 
nociception.  In contrast, a stroke in the area of the thalamus may lead to the severe and chronic 
experience of pain in the absence of peripheral nociception.   
We can model pain and study nociception through the use of animal models.  As Jeffery Mogil 
has pointed out “We might never be able to know what pain feels like in a rat, but we will never 
know what pain feels like in you either” (Mogil et al., 2010). Pain is a subjective experience in 
both humans and animals, and we infer pain only by observing behavior.  To infer the magnitude 
of bladder pain in both humans and animals, one commonly used technique is to measure a 
visceromotor response during the application of a noxious stimulus to the bladder.  
VMR Recording in Response to Urinary Bladder Distention (UBD)  
Visceromotor responses (VMRs) are the reflex contraction of abdominal muscles, and the 
magnitude of VMRs has been used as a tool to measure noxious visceral stimuli or analgesia 
(Ness and Gebhart, 1990).  Three criteria are necessary for a valid measure of visceral pain:  the 
measured responses must be (1) reliable and reproducible, (2) inhibited by known analgesics, (3) 
and they must not be inhibited by nonanalgesics (Ness, 1999).  The measurement of VMR in 
response to urinary bladder distention (UBD) fits these criteria.  In this model of visceral pain, 20 
seconds of graded UBD (10 mm Hg to 80 mm Hg in 10 mm Hg steps) produced graded, reliable 
and reproducible VMR responses (increased abdominal muscle contractions) (Ness and Elhefni, 
2004).  The evoked response (VMR) to UBD was reversibly inhibited by morphine and 
intravesicular (injected into bladder) lidocaine, but not affected by the vehicle used to deliver them 
(Ness and Elhefni, 2004).  In addition, intravesicular mustard oil (known to produce inflammation) 
results in a significant increase in evoked response to UBD (Ness and Elhefni, 2004).  The 
evoked response (VMR) is a spinobulbospinal reflex to bladder distention, observed in 
decerebrate mice/rats but not in mice/rats with a transected spinal cord (Castroman and Ness, 
2001; Ness et al., 2001; Ness and Elhefni, 2004).  Bladder distention reliably produces pain 
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and/or discomfort in humans (Ness et al., 1998), and is frequently used in rats as a visceral pain 
model (Ness et al., 2001).  Recently this visceral pain model was adapted for mice (Ness and 
Elhefni, 2004). We used this technique in thesis chapters 2-4 to measure distention-induced 
bladder pain in mice.  See Figure 1.2 for a schematic of the VMR. 
 
Figure 1.2 Illustration of in vivo urinary bladder distention visceromotor response (VMR) setup.   
Compressed air guided into the bladder with a catheter is used to distend the bladder.  Distention 
induces a visceromotor response that is recorded as an electromyogram (EMG) from the 
abdominal muscles.  Representative EMG traces show that the VMR response increases with 
increasing bladder distention pressure.   
Structure and Innervation of the Bladder 
Kidneys are essential to mammalian survival in part because they function to filter hazardous 
substances out of the bloodstream and excrete them as urine.  The urinary bladder is a highly 
distensible organ that prevents the constant release of urine by storing it until disposal 
(micturition) is appropriate.  The epithelial lining of the bladder, the urothelium or uroepithelium, is 
highly specialized watertight barrier designed to prevent toxic components of urine to diffuse 
across during prolonged storage (Hicks et al., 1974).  The urothelium of the mammalian bladder 
contains three cell layers: the superficial facet cell (SFC, also known as umbrella cells, facet cells 
or superficial cells) layer, intermediate cell layer and the basal cell layer (Hicks, 1975; Truschel et 
al., 1999).  SFCs form a single layer of highly differentiated and polarized cells on the apical 
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surface of the bladder.  They are either mono or multinucleate (species dependent), polyhedral, 
and between 25-250 micrometers in diameter (dependent on filling state of bladder) (Hicks, 1975; 
Truschel et al., 1999).  SFCs have distinct apical and basolateral membrane domains that are 
demarcated by tight junctions.  The tight junctions of the SFCs create the impermeable barrier of 
the bladder wall (Khandelwal et al., 2009).   
The intermediate cell layer is found just below the SFCs.  Intermediate cells rapidly 
differentiate when the overlying SFC is sloughed off to repopulate the SFC layer (Khandelwal et 
al., 2009).  In rodents, the intermediate cells are 1-2 layers thick while humans have up to five 
layers of intermediate cells (Jost et al., 1989).  However, through unknown mechanisms, the 
apparent number of intermediate cell layers is highly dependent on the filled status of the bladder 
(Jost et al., 1989).  The change in the number of intermediate cell layers may be one of the 
mechanisms by which the bladder is highly distensible.  Furthermore, intermediate cells are 
mononucleate and ~10-15 micrometer in diameter (Hicks, 1975). Beneath the intermediate cell 
layer, is the basal cell layer. This layer consists of mononucleated cells ~10 micrometer in 
diameter, and the urothelium is continuously repopulated by stem cells within the basal layer 
(Kurzrock et al., 2008).  Normal turnover of the urothelium takes 3-6 months (Hicks, 1975; Jost, 
1989), but rapid renewal of the urothelium can initiate within hours following injury such as 
bladder infection (Mulvey et al., 1998; Mysorekar et al., 2002)  
Role of the Urothelium in IC/PBS 
Abnormal urothelial turnover is common to multiple painful disease states including: recurrent 
urinary tract infections (UTIs), interstitial cystitis/PBS, and bladder cancer.  It has been 
hypothesized that damage to the urothelium leads to the development of IC/PBS (Parsons, 2007; 
Hanno et al., 2010). Disruption of urothelial integrity may be linked to expression of substances 
such as antiproliferative factor (see figure 1.1), which has been detected in the urine of patients 
with IC/PBS and may be related to the development of IC/PBS (Keay et al., 2004a; Keay et al., 
2004b).  Disruption of the impermeable urothelial barrier, leads to urinary solutes (such as 
potassium) causing tissue injury and pelvic nerve sensitization (Parsons, 2007).  However, the 
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specific components of urothelial injury and the molecular signals generated by this injury that 
lead to bladder pain are not known.  In chapter 2 of this thesis, we investigate how distinct 
urothelial injury models influence bladder pain.  Additionally we aimed to tease out the unique 
molecular signals that are responsible for urothelial injury versus those that modulate pain. 
Urothelium Injury Models 
We used three models of bladder injury to induce proliferation and damage to distinct layers of 
the urothelium (Uropathogenic E. coli (UPEC), Protamine Sulfate (PS) and lipopolysaccharide 
(LPS)) (Mysorekar and Hultgren, 2006; Mysorekar et al., 2009; Shin et al., 2011).  See Figure 1.3 
for a summary of the injury models.  
 
Figure 1.3: Summary of Bladder Injury Models. 
UPEC Injury Model: Urinary tract infections are the most common community or hospital acquired 
bacterial infection, and the most common reason young women seek medical attention (Baerheim 
and Hunskar, 1997; Hooton and Stamm, 1997).  Uropathogenic Escherichia coli (UPEC) account 
for over 80% UTI’s (Ronald, 2003), and a murine model of bladder injury as the result of UPEC 
infection has been well characterized and established (Hung et al., 2009).  24 hours following 
Infection with UPEC induces urothelial barrier damage, inflammation as well as activation of cells 
in the basal cell layer (Mysorekar and Hultgren, 2006; Hung et al., 2009; Mysorekar et al., 2009).  
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UPEC infection induces a rapid recruitment of neutrophils into the bladder lumen and urothelial 
production of inflammatory chemokines and cytokines (Hang et al., 2000; Schilling et al., 2003).  
The rapid immune response is due to virulence factors on UPEC such as LPS, flagella, type I pili, 
and papa pili (Hedlund et al., 2001; Zhang et al., 2004).  Recently, UPEC strain (NU14) was 
demonstrated to increase referred mechanical sensitivity, possibly due to LPS (Rudick et al., 
2010).  However, it is previously unknown if a bladder infection with UPEC increases sensitivity to 
bladder distention.   
PS Injury Model: PS is a highly cationic peptide that is used clinically to reverse the anticoagulant 
effects of heparin.  Intravesicular PS treatment results in exfoliation of the SFC barrier (Mysorekar 
and Hultgren, 2006) and increased ionic permeability of the urothelium (Tzan et al., 1993). Low 
dose intravesicular PS (10mg/ml) chemically exfoliates the SFCs within the first 12 hr (Mysorekar 
and Hultgren, 2006), resulting in a ‘leaky urothelium’ and proliferation of the intermediate cell 
layer (Mysorekar et al., 2009).  Low dose intravesicular treatment with PS does not induce 
bladder hyperactivity (Chuang et al., 2003), or inflammation of the urothelium (Mysorekar and 
Hultgren, 2006; Mysorekar et al., 2009).     
LPS Injury Model: LPS is a large molecule found on the outer membrane of Gram-negative 
bacteria.  LPS binds Toll-Like receptor 4 (Poltorak et al., 1998), and is the most common bacterial 
product instilled into the bladder to cause cystitis in laboratory models.  Intravesicular instillation 
of LPS induces inflammation of the urothelium without exfoliation of SFCs (barrier damage) 
(Saban et al., 2002).   
In chapter 2 of this thesis, we use these differential models of bladder injury to examine how 
distinct urothelial injury affects bladder pain.  Furthermore, we can follow the expression of 
cytokines that are known to modulate both pain and injury.  In this way, we can start to tease out 
the unique molecular signals that are responsible for urothelial injury versus pain.   
Sensory Innervation of the Bladder 
Although bladder submucosal granulations, hemmoragic tissue and mucosal denudation are 
frequent histological findings in IC/PBS, they are not pathognomonic.  Indeed, 50% of patients 
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with IC/PBS have histologically normal bladder biopsies (Rosamilia and Dwyer, 2000). In such 
cases, it is possible that molecular changes in nerves that innervate the bladder, the spinal cord 
or the brain may be the source of chronic bladder pain (a type of visceral pain).  
The sensory innervation of the urinary bladder is associated with two principal pathways; the 
sacral pelvic (parasympathetic) and hypogastric/lumbar splanchnic (sympathetic) innervations 
(Xu and Gebhart, 2008).  Despite the suggestive names, the afferent nerves are distinct from 
efferent, autonomic, pathways (Robinson and Gebhart, 2008).  Axonal tracing studies in cats and 
rats have demonstrated that the pelvic afferent innervation (de Groat et al., 1990; Fall et al., 1990; 
Habler et al., 1990) of the bladder terminate at spinal cord level L6-S1 with their cell bodies 
located in L6 and S1 DRGs (de Groat, 1993).  Furthermore, the hypogastric/lumbar splanchnic 
afferents from the bladder terminate at spinal cord levels L1-L2, and the cell bodies of the 
afferents are in the L1 and L2 DRGs (Moss et al., 1997; Nazif et al., 2007).  Both the pelvic (L6-
S1) and the hypogastric (L1-L2) nerves are thought to convey nociceptive signals (Xu and 
Gebhart, 2008; James I. Gillespie, 2009).   
Nociceptors are defined as a high-threshold sensory receptor of the peripheral somatosensory 
nervous system that iscpable fo transducing and encoding noxious stimuli (IASP, 2011).  The cell 
body of each nociceptor is located in the dorsal root ganglion (DRG) or trigeminal ganglion.  
Nociceptive information is transmitted from the periphery to the spinal cord, where nociceptors 
synapse on the second order neurons in the dorsal horn (central terminals).  From the spinal 
cord, this nociceptive information is conveyed to rostral structures.  Following injury or 
inflammation, increased sensitivity to pain (hyperalgesia) occurs by several mechanisms.  First, 
nociceptors may become sensitized in a process termed peripheral sensitization, during which 
nociceptor activation thresholds are reduced and/or increased firing rates.  One possible 
mechanism by which central sensitization may occur is by increased excitability of neurons within 
the CNS.  Peripheral and/or central sensitization is one way that chronic pain has been 
hypothesized to be initiated and maintained.  Chronic visceral pain (such as bladder pain) may 
also be the result of peripheral and/or central sensitization.   
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Visceral Pain is Different than Somatic Pain  
Much of what is known about nociception comes from studies of nociceptors from non-visceral 
structures such as the integument (Robinson and Gebhart, 2008). Clinically, visceral pain is often 
treated as a variant of somatic pain; under the assumption that the same neurological 
mechanisms may be responsible for both visceral and somatic pain (Gebhart, 2000a).  However, 
conventional treatments for visceral pain are often ineffective, indicating significant differences 
between visceral and somatic pain (Robinson and Gebhart, 2008).  This may be due to intrinsic 
differences between visceral nociceptors and non-visceral nociceptors (Gebhart, 2000b, 2004; 
Robinson and Gebhart, 2008).   
Visceral and somatic afferents differ in several ways.  First, in somatic structures there is a clear 
division between nociceptor afferents and low-threshold afferents (Sengupta and Gebhart, 1994; 
Cervero and Laird, 1996).  Nociceptor afferents detect noxious or potentially damaging stimuli, 
while low-threshold afferents detect non-noxious stimuli.  However, in the viscera this distinction 
is not as clear; for example, visceral low-threshold mechanosensory afferents encode organ 
distention over a wide range from innocuous to noxious pressures (Robinson and Gebhart, 2008).  
On the other hand, visceral high-threshold receptors are activated by stimuli only in the noxious 
range (Cervero and Laird, 1999).  Furthermore, visceral organs have been reported to have 
‘silent’ nociceptors that are only activated in the context of inflammation (Robinson and Gebhart, 
2008).  Second, cutaneous/somatic receptors are more specialized; different types of nerve 
ending (such as ruffini endings and pacinian corpusles) respond to distinct insults.  In contrast, a 
high percentage of visceral afferents are sensitive to stimuli from multiple modalities (mechanical 
distention, chemical and thermal stimuli) (Robinson and Gebhart, 2008).  Third, visceral organs, 
unlike somatic structures, are usually innervated by two additional sources; sympathetic and 
parasympathetic nerves (Christianson et al., 2009).  Fourth, visceral afferents terminate in 
different lamina of the spinal cord when compared to non-visceral afferents.  Visceral afferent 
fibers terminate in lamina X in addition to the superficial dorsal horn and lamina V, where non-
visceral nociceptors terminate only in the superficial dorsal horn and lamina V (Christianson et al., 
2009). Thus, there are major differences between visceral and somatic nociceptor anatomy and 
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physiology.    
mGluR5 Regulates Inflammatory Pain Signaling  
Glutamate is the predominant excitatory neurotransmitter in the mammalian nervous system.  It 
mediates transmission of nociceptive information from the periphery to the spinal cord (Fundytus, 
2001; Varney and Gereau, 2002).  When glutamate is released from the sensory afferents onto 
the spinal cord dorsal horn neurons, it can activate two major classes of glutamate receptors; 
ligand-gated ionotropic glutamate receptors (iGluRs) and G-protein coupled metabotropic 
glutamate receptors (mGluRs).  mGluR5 is found throughout the CNS and peripheral nervous 
system (PNS) (Lu et al., 1997; Varney and Gereau, 2002). Antagonists of mGluR5 such as MPEP 
and fenobam reversed or reduced thermal and mechanical hyperalgesia induced by cutaneously 
applied pro-inflammatory agents including complete Freund’s adjuvant (CFA), formalin, 
glutamate, capsaicin, and carrageenan with no effect on baseline sensitivities (Fisher and 
Coderre, 1996; Zhou et al., 1996; Walker et al., 2001a). Furthermore, mGluR5 knockout mice and 
their WT littermates have similar baseline thermal and mechanical sensitivities (M. Montana, 
unpublished observations (Lu et al., 1997)).  However, mGluR5 knockout mice display reduced 
nocifensive behavior in the formalin test (Montana et al., 2009).  Suggesting that in somatic 
inflammatory pain, mGluR5 has a role in sensitization of peripheral afferents and/or the 
development of central sensitization (Hunskaar and Hole, 1987; Montana et al., 2009).  Although 
much is known about the role of mGluR5 in somatic inflammatory nociception (Walker et al., 
2001c; Walker et al., 2001a; Fisher et al., 2002; Hudson et al., 2002; Varney and Gereau, 2002), 
there is very limited data on the role/site of action of mGluR5 in visceral pain (Lindstrom et al., 
2008).  
In chapter 3 of this thesis, we examine the role of mGluR5 in inflammatory and non-inflammatory 
bladder pain.  Using mGluR5 KO mice and a specific antagonist of mGluR5, we demonstrate that 
mGluR5 is necessary for the full expression of distention-induced bladder pain.  Furthermore, 
through the use of UPEC-induced infectious cystitis and a specific antagonist to mGluR5, we 
demonstrate that mGluR5 is necessary for the full expression of inflammatory bladder pain.  
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However, in all of these experiments (mGluR5 KO and antagonist), activation of mGluR5 was 
blocked indiscriminately with respect to anatomical loci: mGluR5 KO mice lack mGluR5 
throughout the PNS and CNS (global KO) and the specific antagonist of mGluR5 (fenobam) 
easily and quickly crosses the blood-brain-barrier (Montana et al., 2009).  Therefore, these data 
do not distinguish where mGluR5 activation is important for regulating bladder pain.     
mGluR5 and the Pain Neuroaxis:  
Group I mGluRs (mGluR1 and 5) have been demonstrated to have a pro-nociceptive role in many 
parts of the nervous system including the spinal cord, periphery, brainstem, thalamus, cortex and 
amygdala (Bhave et al., 2001; Walker et al., 2001d; Zhou et al., 2001; Neugebauer and Carlton, 
2002; Neugebauer and Li, 2002; Varney and Gereau, 2002) (see Figure 1.4).  mGluR5 is 
expressed on peripheral terminals of unmyelinated nociceptors (Bhave et al., 2001), and 
intradermal administration of mGluR5 agonists induces mechanical (Walker et al., 2001c) and 
thermal hypersensitivity (Bhave et al., 2001; Walker et al., 2001b; Hu et al., 2002; Neugebauer 
and Carlton, 2002). Importantly, in somatic pain models, antagonists of mGluR5 had no effect on 
normal thermal or mechanical nociception (Bhave et al., 2001; Walker et al., 2001d; Kolber et al., 
2010).  mGluR5 expression has been detected in the small diameter DRG neurons of L1-2 and 
L6-S1 (Valerio et al., 1997; Ghosh et al., 2007).  However, it is unknown if mGluR5 is expressed 
in the bladder.  Recent work implies that central and not peripheral mGluR5 modulates distention-
induced bladder pain (Hu et al., 2009).  In that study, the authors used an in-vitro rat bladder-
nerve preparation to measure pelvic nerve firing in response to bladder distention (Hu et al., 
2009).  The rate of nerve firing in response to bladder distention was unchanged by the presence 
of an mGluR5 antagonist (MPEP).  These results suggest that the site of action of this mGluR5 
antagonist is in the CNS and not in the bladder (Hu et al., 2009).   
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Figure 1.4 A simplified model of the pain neuroaxis and mGluR5 expression.  Afferent nerves 
from the bladder (pelvic and hypogastric nerves) synapse in the spinal cord.  The signal is then 
transmitted to the thalamus via the spinothalamic tract.  The amygdala (central nucleus of the 
amygdala or CeA) receives nociceptive-specific information by way of the brainstem via the 
spino-parabrachio-amygdaloid pain pathway (simplified in Figure 1.3).  Highly processed 
polymodal (including nociceptive) information reaches the amygdala (lateral and basolateral 
amygdala) by way of the thalamus.  The CeA integrates polysensory and nociceptive-specific 
information (Neugebauer et al., 2004). Descending information from the CeA travels to the spinal 
cord through circuits connecting the periaquiductal Grey (PAG) and the rostral ventromedial 
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In the spinal cord, mGluR5 has been detected pre- and postsynaptically in the superficial dorsal 
horn (Neugebauer, 2002).  Intrathecal injection of DHPG, a group I mGluR (mGluR1/5) agonist, 
results in spontaneous nociceptive behavior that includes licking of the hindpaw, tail and flanks.  
Pretreatment with selective mGluR1 and mGluR5 antagonists, significantly attenuated the DHPG-
induced nociceptive behavior, indicating that DHPG does not produce the nociceptive effects via 
a nonspecific mechanism (Fisher and Coderre, 1996; Karim et al., 2001a).  
In addition to the spinal cord, mGluR5 is present throughout the pain neuroaxis, including within 
the amygdala.  The amygdala is an important limbic region that is involved in processing 
emotional and motivational aspects of pain. The central nucleus of the amygdala (CeA) receives 
direct nociceptive information from the spinal cord and brainstem and indirect sensory (including 
nociceptive) information (via lateral and basolateral amygdala nuclei (BLA)) via the thalamus and 
cortex (Bernard and Besson, 1990; Burstein and Potrebic, 1993; Bernard et al., 1996; Bourgeais 
et al., 2001) (see Figure 1.4).  The CeA is known to play an important role in processing of 
somatic and visceral pain.  Noxious colorectal distention increases c-fos expression in the CeA 
(Traub et al., 1996) and the excitability of CeA neurons increases after induction of zymogen-
induced colitis in rats (Han and Neugebauer, 2004).   
Outputs from the CeA to the hypothalamus (involved in autonomic regulation) and brainstem 
regions such as the periaqueductal gray (PAG; involved in descending pain modulation) make the 
amygdala well positioned to modulate behavioral responses to painful stimuli.  Chronic activation 
of the CeA with corticosterone implants increases visceromotor responses to colorectal and 
noxious bladder distention in rats and sensitizes afferent visceral spinal neurons (Greenwood-
Van Meerveld et al., 2001; Qin et al., 2003a, b; Qin et al., 2003c; Myers et al., 2005; Myers et al., 
2007; Myers and Greenwood-Van Meerveld, 2010).  The mechanism of these effects is unknown, 
but it likely involves transcriptional changes maintained by corticotropin-releasing factor signaling 
(Qin et al., 2003c; Myers and Greenwood-Van Meerveld, 2010). Nonetheless, it is undetermined 
if acute changes in excitability of CeA neurons modulate the response to noxious bladder 
stimulation.  
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The excitability of CeA neurons is modulated in part by metabotropic glutamate receptor 5 
(mGluR5) signaling (Ji, 2004). Pharmacological mGluR5 activation in the CeA increases rectal 
distention-induced neuronal responses (Ji and Neugebauer, 2010) and behavioral vocalizations 
(Li et al., 2011).  Furthermore, our lab (Carrasquillo and Gereau, 2008; Kolber et al., 2010) and 
others (Ji and Neugebauer, 2009; Li et al., 2011) have shown a primary role for the right 
amygdala in somatic and visceral pain. Activation of mGluR5 in the right CeA is sufficient to 
induce peripheral hypersensitivity in the absence of injury (Kolber et al., 2010).  Furthermore, 
injury-induced peripheral hypersensitivity is resolved by blocking mGluR5 activation in the right 
CeA.   
In Chapter 4 of this thesis we use right CeA pharmacologic activation and inhibition of mGluR5 as 
well as conditional deletion of mGluR5 to determine the role of CeA-specific mGluR5 signaling in 
bladder pain.  In addition, we used an optogenetic approach to stimulate CeA neurons to 
determine if increased activation of the CeA increases the VMR to noxious bladder distention. 
Overall, we found that either mGluR5 activation in the CeA or increased excitability of neurons in 
the right CeA is sufficient to induce increased responses to bladder distention. These results 
demonstrate a role for mGluR5 in the modulation of bladder pain in the absence of injury.     
mGluR5 and ERK: 
Rodent models of pain have demonstrated that mGluR5 signaling to extracellular regulated 
kinase 1/2 (ERK1/2) may play a key role in peripheral and central sensitization (Karim et al., 
2001c; Adwanikar et al., 2004; Kawasaki et al., 2004; Hu et al., 2007). Intrathecal administration 
of an mGluR5 antagonist significantly attenuated formalin-induced phosphorylation of ERK1/2 in 
the spinal cord (Karim et al., 2001b).  Furthermore, recent work in our lab demonstrates that 
noxious bladder distention results in activation (phosphorylation) of ERK1/2 in the lumbosacral 
spinal cord (Lai et al., 2011).  In addition, intrathecal  antagonism of an ERK1/2 inhibitor was 
analgesic in non-inflammatory and cyclophosphamide-induced inflammatory distention-induced 
bladder pain.  mGluR5 signaling to ERK1/2 has been hypothesized to play a role in the 
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modulation of pain responses at the level of the spinal cord and amygdala (Ji, 2004), yet it is 
unknown if mGluR5 signals to ERK1/2 in bladder pain.  
Intraplantar formalin results in mGluR5 mediated ERK activation in the CeA.  However, the role of 
amygdala ERK1/2 in bladder pain is undetermined.   In chapter 4 of this thesis, our results 
suggest that mGluR5 in the right CeA modulates distention-induced ERK1/2 activation in the 
lumbosacral spinal cord.  We found that noxious bladder distention alone leads to ERK1/2 
activation in the lumbosacral spinal cord, but not ERK1/2 activation in the amygdala.  
Surprisingly, conditional deletion of mGluR5 in the right CeA results in decreased ERK1/2 
activation in the spinal cord following bladder distention.  Furthermore, optogenetic stimulation of 
CeA neurons leads to both an increased response to bladder distention and increased ERK1/2 
activation in the spinal cord following noxious bladder distention.  However, optogenetic activation 
alone (no bladder distention) of the right CeA does not increase ERK activation in the 
lumbosacral spinal cord.  Thus suggesting that bladder distention leads to ERK1/2 activation in 
the lumbosacral spinal cord and mGluR5 in the right CeA can modulate distention-induced 
ERK1/2 activation in the spinal cord       
 In chapters 2-4 of this thesis, we examine three aspects of bladder pain.  First, in chapter 2, we 
examine if distinct urothelial injury leads to differential evoked responses to bladder distention.  
Second, in chapter 3, we investigate the role of mGluR5 on distention induced bladder pain.  
Third, in chapter 4, we investigate how mGluR5 in the right CeA modulates bladder pain and 
distention-induced ERK activation in the lumbosacral spinal cord.  In summary, the work in this 
thesis examines modulation of bladder pain from the level of the bladder, spinal cord and brain.   
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ABSTRACT 
 
Purpose: Bladder pain is a debilitating symptom of many urologic conditions, and there is no 
generally effective treatment. Abnormal urothelial turnover is common to multiple disease states, 
but the specific components of urothelial injury and the resulting molecular signals that lead to 
bladder pain are unknown. We examined mouse models of bladder injury induced by 
uropathogenic E. coli (UPEC), protamine sulfate (PS), and bacterial lipopolysaccharide (LPS) to 
identify cellular and molecular correlates underlying pain sensitization in response to the stimuli. 
 
Materials and Methods: C57BL/6 female mice were given intravesicular PS, LPS or UPEC, and 
the impact of each on nociception was determined by measuring the evoked visceromotor 
response to bladder distention at 24 hours post inoculation. Levels of pyuria and tissue 
inflammation were examined by urinary cytology and tissue histology. Quantitative PCR and gene 
expression analysis were used to identify injury profiles associated with nociception. 
 
Results: PS treatment was significantly analgesic upon bladder distention. PS-treated bladders 
did not exhibit pyuria or extensive tissue damage. PS injury was associated with a global 
decrease in expression of inflammation-associated genes. In contrast, UPEC injury significantly 
increased the nociceptive response to bladder distention. LPS treatment did not affect 
nociception. Finally, injury-induced expression of inflammation-associated genes correlated with 
nociceptive responses. 
 
Conclusion: PS treatment of the bladder is analgesic, tissue protective, and suppresses 
inflammatory cytokine expression normally associated with nociception. Additionally, the injury 
modalities that result in differential tissue response patterns provide an innovative method for 
identification of mediators of visceral pain. 
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INTRODUCTION  
	  
The bladder is the site of several urologic conditions, and abnormal urothelial turnover is 
common to multiple painful disease states including interstitial cystitis/bladder pain syndrome 
(IC/BPS) and urinary tract infections (UTIs). IC/BPS and UTIs share the common clinical feature 
of increasing pelvic pain upon bladder filling (distention) leading to urinary frequency and 
urgency, with bladder pain being the most frequent reason for physician visits (Warren et al., 
2008). IC/BPS affects 3-6% of women in the US (Berry et al., 2011). UTIs, caused primarily by 
uropathogenic E. coli (UPEC), affect 13 million women each year (Foxman, 2010). 
 Urothelial cell sloughing and defective urothelial barriers characterize patients with 
recurrent/chronic UTIs and IC/BPS. Disruption of the normally impermeable urothelial barrier 
leads to tissue injury and pain sensitization (Parsons, 2007). Although the urothelium is 
recognized as a nociceptive (pain)-sensing structure that modulates and transmits noxious stimuli 
through mediators such as cytokines and ATP (Keay, 2008; Birder et al., 2012), it is unclear how 
damage to each tissue layer of the bladder affects pain, and the specific molecular components 
generated by urothelial tissue injury that lead to bladder pain are unknown.  
The urothelium exhibits a remarkable ability to renew in response to environmental 
insults (e.g., pathogens and cytoinjurious factors). Intriguingly, the regenerative responses to 
injury modalities are distinct (Mysorekar et al., 2009). A murine model of bladder injury resulting 
from UPEC infection leads to urothelial barrier damage and inflammation within 24h (Mysorekar 
et al., 2009). Urothelial regeneration following infection is fueled by a rapid activation of stem and 
early progenitor cells (Mysorekar et al., 2009). In contrast, intravesicular treatment with protamine 
sulfate (PS), a highly cationic peptide that causes increased ionic permeability of the urothelium 
and chemically exfoliates urothelial barrier cells within 12h of instillation, does not induce 
inflammation (Tzan et al., 1993; Mysorekar et al., 2009). Rather than activating urothelial stem 
cells, PS-induced injury appears to activate epithelial repair via transiently amplifying cells 
(Mysorekar et al., 2009).  
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We used these two well-characterized models of urothelial damage to dissect the cellular 
and molecular mechanisms underlying pain sensitization in response to injury and inflammation. 
We report a striking protection from distention-induced bladder pain upon PS injury, which is in 
contrast to the nociceptive response triggered by UPEC infection. Urine cytology and tissue 
histology show that PS treatment protects against pyuria and distention-induced tissue damage. 
Finally, we identified a molecular profile of globally down-regulated inflammatory cytokines with 
an increase in transient amplifying cell signatures, thus providing novel insights into the 
mechanisms of nociception and PS-induced analgesia.  
 
MATERIALS AND METHODS 
Mice 
All animal experimental protocols were approved by the Washington University Institutional 
Animal Care and Use Committee. Female C57BL/6 mice (Jackson Laboratory, Bar Harbor, ME), 
9-13 weeks old were used for all experiments. Animals were housed on a 12-hour light/dark cycle 
and allowed ad libitum access to food and water.  
Intravesicular inoculations 
UTI89, a pathogenic Escherichia coli strain, was grown statically in Luria-Bertani (LB) broth for 17 
h at 37 oC. 50 µl of PS (10 mg/ml in water; Sigma, St. Louis, MO) or 107 colony-forming units 
(CFU)/mL bacterial suspensions in saline were intravesicularly administered.(Hung et al., 2009; 
Mysorekar et al., 2009) Littermate controls received 50 µl of sterile 1x saline (Fisher, Waltham, 
MA). Inflammatory damage was induced with lipopolysaccharide (LPS) (50 µl, 100 µg/ml LPS 
from E. coli strain 055:B5, Sigma) by intravesicular inoculation once a day for four days.(Saban et 
al., 2002) Littermate controls received a four-day administration of 50 µl of 1x sterile saline. After 
intravesicular administration, the catheter was removed, and all animals were maintained under 
isoflurane anesthesia for 10 minutes before spontaneous waking.  
Visceromotor Response (VMR) analysis 
At 24 hours post last inoculation (hpi), animals were lightly anesthetized under isoflurane and the 
visceromotor response (VMR) of each animal was recorded. Visceral nociception was quantified 
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by an electromyographic recording of the abdominal muscle response to bladder distention as 
described previously (Ness and Elhefni, 2004; Lai et al., 2011; Crock et al., 2012). For each 
distention, the VMR signals were subtracted from the baseline, rectified, and integrated over 20 
seconds to quantify the area under the curve.  
Tissue preparation and inflammation scoring  
Immediately following completion of VMR analysis, mice were sacrificed, and bladder and kidney 
tissues were aseptically removed. Tissues were fixed in methacarn (60% methanol, 30% 
chloroform, 10% glacial acetic acid), embedded in paraffin, sectioned, and stained with 
hemotoxylin and eosin. Photomicrographs were taken using a Hamamatsu NanoZoomer 
HT (Hamamatsu Corporation) and observed in a blinded fashion to score the level of tissue 
damage and inflammation using a modified semi-quantitative scoring system (Hannan et al., 
2010): 0, normal; 1A, subepithelial edema without cellular infiltrate; 1B, subepithelial inflammatory 
infiltration (focal and multifocal); 2, edema and subepithelial inflammatory infiltration (diffuse); 3, 
marked subepithelial inflammatory cells with necrosis and polymorphonuclear neutrophils (PMNs) 
in and on bladder mucosal epithelium; 4, grade 3 criteria plus inflammatory infiltrate extends into 
muscle; 5, loss of surface epithelium (necrosis with full thickness inflammatory infiltration).	  
Urine collection, urine sediment, and bacterial titer analysis 
Urines were collected prior to intravesicular treatment, at 6 hpi, 24 hpi, and twice during the VMR 
analysis. Urines collected prior to VMR were obtained as previously published (Hannan et al., 
2010). During VMR rest periods, catheterized animals had gentle pressure applied to the skin just 
below the occiput, and voided urine was gathered by pipet and transferred to sterile tubes. “Non-
noxious pressure” (<30 mmHg distention) and “noxious pressure” (>40 mmHg) urines were 
collected per mouse and pooled. Urine sediments were obtained as previously detailed (Hannan 
et al., 2010), fixed for 15 minutes in acetic acid/alcohol, and Papanicolaou stained following 
manufacturer’s instructions (PROTOCOL brand, Fisher). Photomicrographs were taken using a 
Nikon Eclipse E800 microscope (Japan) and analyzed using Image J (NIH). Stained urine 
sediments were examined and scored in a blinded manner by light microscopy on a 0-4 scale, 
where 0 indicates <1 and 4 indicates >20 PMNs/high-powered field as previously described 
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(Hannan et al., 2010). Pre-treatment urines exhibited no evidence of superficial cell sloughing or 
pyuria prior to intravesicular instillations. Bladder infection was confirmed by spotting serial 
dilutions of urine on LB agar plates and quantifying CFUs after overnight growth at 37 ºC. 
DNA Microarray inflammatory gene profiling 
Total cellular RNA was isolated (RNeasy kit, Qiagen) from whole mouse bladders at 3 hpi, 6 hpi 
(for UPEC), and 3 hpi, 6 hpi, 24 hpi, and 48 hpi (for PS); (8-12 week old female mice, 10 
animals/injury/time point, n=2 independent experiments). cRNAs were generated from pooled 
RNAs and used to interrogate U74 (UPEC) and 430 2.0 whole mouse genome GeneChips 
(Affymetrix) as previously published (Mysorekar et al., 2009). Genes and Gene Ontology (GO) 
terms that were enriched in each treatment were determined using dChip and GOurmet software 
(Doherty et al., 2006). To identify GO terms increased following PS treatment, enriched genes 
were associated with GO terms. GO terms that increased by >25%, and represented >3% of the 
genes expressed at one or more time points were determined. All such GO terms were plotted in 
Figures 2.5C-E. 
Real time quantitative RT-PCR (qPCR) 
Total cellular bladder RNA (TRIzol isolated following manufacturer’s protocols) was pooled (5-7 
animals, 6-11 week old females) from mice at 3.5 hpi, 6 hpi and 24 hpi. cDNAs were reverse 
transcribed, assayed in triplicate, and gene expression changes were determined using the ΔΔCt 
method (normalized to 18s rRNA, and then to saline treated mice) as described (Mysorekar et al., 
2002; Mysorekar et al., 2009). Primer sequences (listed in Table 2.1) were obtained from the 
qPCR PrimerBank public database (Spandidos et al., 2010).  
Statistical analysis 
VMR measurements (mean ±SEM) were analyzed by 2-way ANOVA with Bonferroni post-hoc 
analysis. Inflammation scores were analyzed using two-tailed Mann-Whitney U-tests (where 
appropriate) comparing injuries to their respective controls. 
 
RESULTS  
PS is analgesic in the distention VMR assay  
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We hypothesized that various injuries to the bladder architecture and the respective renewal 
responses may have differential effects on the pain-like response to bladder distention. We have 
previously used the visceromotor response (VMR) to reliably measure hypersensitivity in a 
chemically-induced bladder inflammation model, demonstrating that the VMR is potentiated by 
inflammation (mustard oil, cyclophosphamide, and zymosan) and inhibited by analgesics 
(morphine and intravesicular lidocaine) (Ness and Elhefni, 2004; Lai et al., 2011; Crock et al., 
2012). The abdominal VMR is measured as the electromyographic signals of the external oblique 
muscle. Behaviorally, it corresponds to abdominal withdrawal and nocifensive guarding when an 
animal experiences pain while its bladder is distended. Therefore, the VMR is a surrogate 
measure of distension-evoked visceral nociception and represents a useful model for examining 
how different injuries to the bladder affect distention-induced bladder pain.  
24 hours prior to VMR testing, mice were given intravesicular UPEC, PS or saline 
(control). As expected, UPEC infection significantly increased the evoked response to bladder 
distention when compared to controls (Figure 2.1A). In contrast, PS treatment resulted in a 
significantly decreased VMR when compared to controls (Figure 2.1A). To determine whether the 
differential effect was due to the absence of an inflammatory response in PS injury, we treated a 
separate cohort of mice with intravesicular LPS every 24 hours for 4 days, a regimen previously 
shown to elicit an inflammatory response (Saban et al., 2002). Multi-dose LPS injury did not 
significantly alter the VMR when compared to mice similarly treated with saline (Figure 2.1B). 
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Figure 2.1. PS injury is analgesic to 
bladder distention. A. Female mice were 
administered saline, PS, or UPEC 
intravesicularly prior to VMR. PS-treated 
animals showed a significantly blunted 
VMR (+++p<0.0001) when compared to 
saline controls with 70 and 80mmHg 
pressures (###p<0.0001) eliciting 
statistically significantly decrease in the 
VMR. UPEC-infected animals had a 
significantly higher VMR (***p<0.0001) 
compared to saline controls, and 
sensitization was seen at the highest 
pressures of distention (70 and 80mmHg, 
**p<0.001). B. Female mice administered 
LPS or saline four times over four days 
had no significantly difference in their 
VMR. These data are presented in 
arbitrary units as mean ±SEM, and p-
values were determined by 2-way ANOVA with Bonferroni’s post-hoc test. 
 
PS treatment does not induce pyuria 
To track urothelial injury and the impact of distention on injury profiles, urine was collected for 
sediment analysis. Saline treatment did not induce injury as measured by cytology (Figure 2.2A-
B, G-H). UPEC injury has been shown to result in formation of intracellular bacterial communities 
(IBCs) by 6 hpi. These are shed into the urine along with neutrophils (PMNs) as part of the host 
response (Hannan et al., 2010). Accordingly, we identified IBCs and PMNs in urines from UPEC-
infected mice (Figures 2.2E-F). Analysis of urines from PS-treated mice showed minor cell 
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sloughing prior to distention (Figures 2.2C-D). LPS injury resulted in PMN recruitment by 6 hpi 
without associated loss of superficial cells (Figures 2.2I-J). Urine sediments scored for 
inflammation at time points post injury revealed that UPEC injury lead to sustained pyuria (urinary 
inflammation), whereas PS treatment did not (Figure 2.2K). LPS injury resulted in acute pyuria, 
which was resolved prior to VMR (Figure 2.2K). 
 
 
Figure 2.2. Pyuria is not induced by PS treatment. Representative urine cytology images of 
PAP-stained urine sediments from control and injured (PS, UPEC, LPS) animals. A-B & G-H. 
Saline-treated controls showed minimal urothelial cell sloughing (highly kertanized vaginal cells 
are brown). By 6 hpi, both UPEC (E) and LPS (I) injuries displayed pyuria whereas PS (C) did 
not. IBCs were found throughout UPEC urines (E&F). Black arrows depict PMNs and white 
arrows demark IBCs. K. Urinary inflammation scores from PS- (n=6), UPEC- (n=10), saline- 
(n=8), x4 LPS- (n=6), and x4 saline- (n=4) treated animals. Bars represent median score values. 
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PS treatment induces hematuria at noxious pressures 
Hemorrhagic cystitis is frequently induced upon toxic chemical or infectious instillation into the 
bladder (Traxer et al., 2001). We observed gross and microhematuria in urines and sediments 
from the majority of PS-injured animals (Figures 2.3D, 4/5, 80%), which was not evident in urines 
prior to pathologic bladder distention (Figure 2.3C). The incidence of hematuria from infectious 
injury was far less prevalent (Figures 2.3E-F, 5/10, 50%). Saline treated animals exhibited 
hallmarks of distention-induced microhematuria (Figures 2.3A-B, 4/7, 57%). Moreover, we found 
that levels of hematuria and pyuria were inversely correlated in PS and UPEC injuries (Figures 
2.3G).  
 
Figure 2.3. Noxious distention induces hematuria in PS-injured animals. Representative 
urine cytology images of PAP-stained urine sediments from control and injured animals. A, C, E. 
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Distention-induced sloughing of superficial cells from all animals. At noxious distention pressures 
(>40 mmHg), hematuria was induced in control (B) and PS (D) treated animals. G. Individual PS- 
(left) or UPEC- (right) treated animals showed an inverse correlation between the levels of pyuria 
(urine inflammation score) and hematuria (urine RBC score). Dotted lines partition individual 
animals’ scores from one another. 
 
PS treatment protects against distention-induced exacerbation of injury  
To track architectural changes as a result of both distention and injury, bladders were collected 
immediately following completion of the VMR recordings. We found that control animals displayed 
superficial cell loss and edema of the lamina propria upon distention (Figures 2.4A-B). 
Interestingly, PS injury was not associated with extensive urothelial or stromal damage (Figure 
2.4C) and displayed a relative lack of tissue inflammation (Figure 2.4E). In contrast, histological 
characterization of UPEC-injured bladders after distention revealed stromal edema, urothelial 
damage, and PMN influx (Figure 2.4D, inset) associated with significantly higher tissue 
inflammation scores (Figure 2.4E) when compared to saline-treated controls.  
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Figure 2.4. Histologic analysis shows PS injury protects against distention-induced 
damage. A. H&E of normal bladder histology without injury or distention. B. Saline treated 
bladder after distention showed edema and superficial cell disruption (inset). C. PS treatment 
prevented exacerbated superficial cell loss or edema due to distention. The urothelium and 
stromal compartment appeared almost normal, with no infiltration of immune cells (inset). D. 
Edema and major urothelial barrier disruption occurred in UPEC-infected bladders after 
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inset). Dotted boxes denote area depicted in insets. E. Tissue inflammation scores from control 
(saline n=12; x4 saline n=4) and injured (PS n=6; UPEC n=9; x4 LPS n=5) animals after 
distention. Bars represent median score values. ***p<0.0001. Two-tailed Mann-Whitney U-test 
comparing to saline controls. N.S. = Not Significant. 
 
PS treatment suppresses pro-inflammatory responses 
The bladder and urothelium produce distinct pro-inflammatory cytokines and chemokines in 
response to inflammatory (e.g., CPX, LPS, substance P) and infectious injury (Saban et al., 2001; 
Saban et al., 2002; Hannan et al., 2010; Wood et al., 2011).  Pro-inflammatory cytokines (e.g., IL-
6, IL-1β) can also lead to pain hypersensitivity (Binshtok et al., 2008; Ren and Dubner, 2010). To 
determine how PS treatment regulates inflammation, we compared gene expression in bladders 
from mice treated with PS to mice infected with UPEC. UPEC infection lead to increased 
expression of genes with ‘inflammation/immune response’ GO terms, whereas PS down-
regulated the expression of those genes (Figures 2.5A-B) (Doherty et al., 2006). Nearly 10 % of 
all genes enriched by UPEC at 6 hpi were characterized by the GO term ‘inflammatory response’, 
whereas only about 0.1% of those enriched in the PS at 48 hpi were characterized as having 
‘chemokine activity’, indicating that the molecular signatures of bladder responses to PS were 
distinct from those induced by UPEC infection.  
Microarray analysis following PS injury revealed an increase in expression of genes that 
function in tissue renewal mechanisms (Figures 2.5C-E). At early time points (6h and before, 
Figure 2.5C), genes related to signaling and cell adhesion were elevated, and by 12h, GO terms 
like ‘DNA replication’ and ‘cell cycle’, which characterize transient amplifying cells but not stem 
cells, were induced (Figure 2.5D).  
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Figure 2.5. Global gene expression profiles after UPEC or PS injury reflect nociception 
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inflammatory state by 6 hpi. B. PS injury resulted in a global decrease in pro-inflammatory gene 
expression by 24 hpi maintained through 48 hpi. C-E. PS treatment induced increases in various 
GO terms that peaked at 6 h (C, early), 12 h (D, mid), or 24 h (E, late). The genes peaking at 6 h 
were associated with cell cycling, whereas those at 12 h had to do with transiently amplifying cell 
populations. F-I. qPCR analysis confirms inflammatory profiles of UPEC and PS injuries, where 
the pro-inflammatory, pro-nociceptive cytokines IL-1β (F) and IL-6 (G) were up-regulated by 
UPEC and down regulated by PS injury relative to untreated bladder. Socs3 was also up-
regulated by UPEC and down-regulated by PS injury (H). Infection decreased mRNA expression 
levels of the anti-inflammatory cytokine, IL-4 (I) and PS injury up-regulated it by 24 hpi. Significant 
fold changes indicated by dotted line at ±2 fold. 
 
We further confirmed these results by identifying multiple gene expression profiles that 
correlated between injury and its respective nociception response by qPCR (Figures 2.5F-I and 
Table 2.1). UPEC injury triggered an up-regulation of the early pro-inflammatory cytokines, IL-1β 
and IL-6, and of Socs3, a negative regulator of IL-6. Furthermore, infection with UPEC resulted in 
down-regulation of the anti-inflammatory cytokine, IL-4, but PS treatment correlated with an up-
regulation of this cytokine. In contrast, PS injury resulted in down-regulation of IL-1β, IL-6, and 
Socs3 (Figures 2.5F-I). We have also identified molecular markers that were up-regulated by both 
UPEC and PS treatments or only regulated by UPEC or PS injury (Table 2.1). 
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Table 2.1. Inflammatory 
genes are differentially 
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DISCUSSION  
 
Here we report that different bladder injuries result in distinct alterations in nociception and 
provide several lines of evidence that this is due to differential effects on inflammation. We find 
that although UPEC infection causes increases in distension-induced pain responses, PS 
treatment reduces these responses. Our urine and tissue inflammation assays and gene 
expression analyses all indicate that the pain modulation correlates with inflammation as a result 
of UPEC infection and suppression of inflammation by PS treatment. 
 Chronic bladder pain is a debilitating condition that is often unresponsive to conventional 
pain medications. Injury-induced sensitization can result in acute pain that resolves, but in some 
instances can transition to chronic pain that persists even in the absence of ongoing injury (Ren 
and Dubner, 2010). Renewal after injury typically requires barrier restoration and resolution of 
inflammation (Mysorekar et al., 2009).	  	  The pathophysiology of conditions such as IC/BPS 
remains poorly understood. Underlying mechanisms include occult UTI, non-infectious idiopathic 
inflammatory changes of the bladder, or urothelial cell sloughing and regeneration. Patients can 
be divided into subsets based on these underlying mechanisms. IC/BPS symptom exacerbation 
(“flare up”) bears remarkable resemblance to recurrent UTI, with increasing bladder pain and 
urinary urgency, and in some cases, may be associated with subclinical UTI (Porru et al., 2004). 
IC urine contains an antiproliferative factor that inhibits the regeneration of bladder epithelial cells 
in culture (Keay, 2008). In IC/BPS and UTIs, disruption of the normally impermeable urothelial 
barrier by continued cell sloughing may further impede renewal and lead to exacerbated tissue 
injury and pain sensitization (Parsons, 2007; Keay, 2008).  
The differential pain response to UPEC, LPS and PS stimuli could in part be explained by 
type of urothelial damage. Consistent with previous findings (Ness and Elhefni, 2004; Rudick et 
al., 2010; Lai et al., 2011; Crock et al., 2012), we find that UPEC infection results in visceral 
hyperalgesia and sensitization of nociceptive responses. UPEC infection appears to activate the 
nociceptive signals transmitted to the central nervous system; inhibition of a key receptor 
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(mGluR5) in this pathway results in a blunted VMR to UPEC infection (Crock et al., 2012). One 
explanation for this activation could be the potent inflammatory response induced upon infection.  
To better study the effect of inflammation on VMR activation, we simplified the complex 
host-pathogen interaction in infection by focusing on inflammation induced by the surface antigen 
LPS. Although adjuvant pre-treatment has been used to increase levels of inflammation (Saban 
et al., 2001; Saban et al., 2002), we treated with LPS alone to mimic the naïve bladder’s 
response to bacterial products. In contrast to adjuvant administration, we found that LPS 
treatment, although displaying acute pyuria, is insufficient to induce changes in VMR. Our 
findings suggest that acute inflammation alone is not critical to evoke bladder pain. Bladder 
distention is known to trigger ATP release from the urothelium, thus activating purinergic 
receptors on superficial cells and sensitizing the afferent neurons (Sun et al., 2001; Munoz et al., 
2011; Birder et al., 2012). Within IC/BPS patients ATP release in response to distention is 
increased (Kumar et al., 2007). It is unknown how other injuries to the urothelium affect the 
release of ATP. Barrier cell sloughing due to PS could deplete the ATP-based sensitization 
mechanism on afferents by lowering ATP levels below an activation threshold (Sun et al., 2001; 
Munoz et al., 2011; Birder et al., 2012). Future work should focus on identifying how urothelial 
status affects the integration of signals important for nociception sensitization. 
Although the presence of a foreign body within the bladder and other PS injury models 
have been shown to result in cystitis-like inflammation (Guiton et al.; Soler et al., 2008), our PS 
injury model uses short catheterization and incubation periods and does not result in 
inflammatory cystitis (Mysorekar et al., 2009). We found that PS injury was analgesic upon 
distention and had improved bladder histology when compared to distended infectious injury and 
controls. This is the first report of urothelial injury eliciting analgesia, but the mechanism by which 
PS treatment is protective is unknown.  
Our microarray analysis revealed contrasting expression profiles in UPEC- and PS-
treated bladders, consistent with the differential effects of UPEC and PS injury on VMR. UPEC 
infection resulted in increased pro-inflammatory gene expression changes within 3-6 hours, 
consistent with molecular changes preceding urothelial stem cell (USC) activation (Mysorekar et 
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al., 2002; Mysorekar et al., 2009). In contrast, we detected decreased expression of 
inflammatory-related genes 24 hours after PS injury. We confirmed the suppressed immune 
response after PS injury by qPCR, focusing on multiple pro-inflammatory and pro-nociceptive 
cytokines. Expression of IL-1β, a pro-inflammatory, pro-nociceptive cytokine that regulates the 
expression of other inflammatory cytokines, and is produced by the bladder in response to 
inflammatory injury (Binshtok et al., 2008; Wood et al., 2011), was decreased in PS injury, but 
increased following UPEC infection. Expression of the pro-inflammatory cytokine IL-6 was 
similarly affected (Hannan et al., 2010; Ren and Dubner, 2010; Blalock et al., 2012). Conversely, 
we observed decreased expression of IL-4, a prototypical anti-inflammatory cytokine, in UPEC-
infected mice but increased expression following PS injury. 
PS injury revealed an increase in renewal mechanisms initiating from transient amplifying 
regulation rather than USC activation (Mysorekar et al., 2009).  It is possible that injuries, such as 
UPEC infection, that activate stem cell-mediated renewal might amplify a feed-forward loop that 
leads to enhanced nociception, whereas injuries like PS that do not activate stem cell-mediated 
renewal do not contribute to increased nociception. Therefore, this combination of suppressed 
immune response and transient amplifying renewal could be contributing to the mode of PS 




We report that various injuries to the bladder lead to differential effects on distention-induced 
nociception. PS injury leads to a decrease in global inflammatory profile expression, is analgesic 
in a model of bladder distention, and decreases the level of injury from distention as compared to 
controls. Our PS injury model provides a new avenue to understand analgesia and how pain is 
sensed in the bladder.  
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Background: Interstitial cystitis/painful bladder syndrome (IC/PBS), is a severely debilitating 
chronic condition that is frequently unresponsive to conventional pain medications. The etiology is 
unknown, however evidence suggests that nervous system sensitization contributes to enhanced 
pain in IC/PBS. In particular, central nervous system plasticity of glutamatergic signaling involving 
NMDA and metabotropic glutamate receptors (mGluRs) has been implicated in a variety of 
chronic pain conditions. Here, we test the hypothesis that mGluR5 mediates both non-
inflammatory and inflammatory bladder pain or nociception in a mouse model by monitoring the 
visceromotor response (VMR) during graded bladder distention. 
Results: Using a combination of genetic and pharmacologic approaches, we provide evidence 
indicating that mGluR5 is necessary for the full expression of VMR in response to bladder 
distention in the absence of inflammation. Furthermore, we observed that mice infected with a 
uropathogenic strain of Escherichia coli (UPEC) develop inflammatory hyperalgesia to bladder 
distention, and that the selective mGluR5 antagonist fenobam [N-(3-chlorophenyl)-N'-(4,5-
dihydro-1-methyl-4-oxo-1H-imidazole-2-yl) urea], reduces the VMR to bladder distention in 
UPEC-infected mice. 
Conclusions: Taken together, these data suggest that mGluR5 modulates both inflammatory 
and non-inflammatory bladder nociception, and highlight the therapeutic potential for mGluR5 
antagonists in the alleviation of bladder pain. 
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BACKGROUND 
Interstitial cystitis/painful bladder syndrome (IC/PBS) is a serious and painful condition of 
unknown etiology that affects 3-6% of women in the United States (Rosenberg et al., 2007; Berry 
et al., 2011).  The major clinical symptom of IC/PBS is pain upon bladder filling (distention) 
leading to urinary frequency and urinary urgency (Warren et al., 2008). The current available 
treatments are often ineffective and do not treat the underlying pathology.  Rodent bladder-injury 
models that induce some of the symptoms observed in IC/PBS have been used to evaluate 
potential treatments for IC/PBS (Maggi et al., 1993; Saban et al., 2002; Westropp and Buffington, 
2002; Dang et al., 2008; Boudes et al., 2011; Lai et al.).  One injury model, bacterial cystitis 
(urinary tract infection, UTI) is known to cause a similar constellation of symptoms as observed in 
IC/PBS (i.e. urinary frequency and urgency (Baerheim and Hunskar, 1997; Malterud and 
Baerheim, 1999; Bower et al., 2005)).  In addition, bacterial cystitis can be modeled in rodents 
through bladder exposure to uropathogenic Escherichia Coli (UPEC) (Mulvey et al., 1998; 
Mysorekar and Hultgren, 2006).   Bladder infections due to UPEC are responsible for 
approximately 80% of UTIs in otherwise healthy women (Foxman, 2002, 2010). Understanding 
the underlying molecular mechanisms of both non-inflammatory bladder pain and inflammatory 
bladder pain due to UPEC infection could lead to the development of novel treatments for painful 
bladder infections as well as for IC/PBS and possibly other visceral pain conditions.   
 
Glutamate is the predominant excitatory neurotransmitter in the mammalian nervous system 
(Matsumoto et al.; Kakizaki et al.; Yoshiyama and de Groat).  Glutamate mediates its effects 
through two major classes of glutamate receptors: ligand-gated ionotropic receptors (iGluRs) and 
G protein-coupled metabotropic glutamate receptors (mGluRs).  Among the metabotropic 
glutamate receptors, one subtype, mGluR5, is of particular interest in the context of pain 
conditions. mGluR5 is expressed throughout the peripheral and central nervous system (Varney 
and Gereau, 2002) and has previously been shown to have a pro-nociceptive role in a variety of 
somatic pain models (Bhave et al., 2001; Karim et al., 2001a; Walker et al., 2001b; Hudson et al., 
2002; Varney and Gereau, 2002; Hu et al., 2007) and some visceral pain models (Bianchi et al., 
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2003; Young et al., 2007; Lindstrom et al., 2008). Specific to visceral pain models, mGluR5 was 
found to modulate gastroesophogeal and colorectal afferent sensitivity (Page et al.; Young et al.; 
Lindstrom et al.).  Based on this prior information, a previous study examined the ability of the 
mGluR5 antagonist, MPEP (2-methyl-6-(phenylethynyl)-pyridine), to reduce bladder pain 
responses in naïve (uninjured) rats (Hu et al., 2009). While this study suggests a potential role for 
mGluR5 in bladder pain, the evidence is based exclusively on the use of MPEP, which has 
recently been shown to act non-selectively in vivo (Montana et al., 2009). Thus, these intriguing 
initial findings are in need of validation. Furthermore, the role of mGluR5 in inflammatory bladder 
pain is unknown.  Here, using a combination of genetic and pharmacological approaches we 
demonstrate that mGluR5 regulates both bladder nociception and normal bladder function in 
naïve mice. Furthermore, we observed an increased VMR to bladder distention in mice infected 
with UPEC.  Finally, UPEC-induced hyperalgesia is reduced by treatment with the specific 
mGluR5 antagonist, fenobam. Together these data strongly support the hypothesis that mGluR5 
is necessary for the full expression of inflammatory and non-inflammatory bladder nociception 
and may be a relevant target for the treatment of bladder pain arising from multiple pathologies, 




mGluR5 is necessary for the full expression of non-inflammatory bladder nociception  To assess 
bladder nociception in response to distension, we utilized the distension-evoked visceromotor 
response (VMR).  The VMR is a spinobulbospinal reflex to bladder distention, increased in 
decerebrate mice/rats and absent in mice/rats with an acute mid thoracic spinal cord transection 
(Castroman and Ness, 2001; Ness et al., 2001; Ness and Elhefni, 2004). Bladder distention 
reliably produces pain and/or discomfort in humans (Ness et al., 1998), and is frequently used in 
rodents as a visceral pain model (Ness et al., 2001; Hu et al., 2009; Lai et al., 2011). To provide 
genetic evidence supporting a role for mGluR5 in bladder nociception, we tested the VMR to 
bladder distention in mGluR5 knock out mice (mGluR5 KO) compared to their WT littermates. 
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Stepwise increases in bladder distension resulted in progressively larger VMR in wild type mice, 
as shown in Figure 3.1B. Furthermore, mGluR5 KO mice showed a statistically significant 
decrease in the evoked response to bladder distention (VMR) in the noxious range of pressures 
when compared to the VMR of WT littermates (p< 0.0001).   
 
Figure 3.1: A. Representative VMR tracings 
from a WT and mGluR5 KO mice. As the 
intravesicular pressure is increased (20-
80mmHg), the EMG activity of the abdominal 
muscle (VMR) is also increased. The total 
amount of activity (area under the curve) 
during the 20 second distention is calculated 
to determine the evoked response at each 
pressure. B. mGluR5 KO (n=18) mice have a 
significantly blunted VMR when compared to 
WT littermates (n=15) +/- SEM,* p<0.05, 
**p<0.01, ***p<0.001. 2-way ANOVA with 
Bonferroni post-hoc test. There were no 
obvious histological differences observed 
between mGluR5 KO mice (1D) and their WT 
littermates (1C). In both, the urothelium 
(above dashed line) has normal layers of 
superficial facet cells (arrows), intermediate 
cells (black arrowhead) and basal cells (white 
arrowhead).   
 
There are several possible reasons that genetic ablation of mGluR5 could lead to the observed 
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and chemical stimuli (Birder, 2010).  One possibility is that loss of mGluR5 could lead to 
anatomical changes in the bladder lining, thus altering the response to distension. We therefore 
examined histological sections from mGluR5 KO mice and their WT littermates. The absence of 
mGluR5 does not appear to impact bladder architecture, as the bladders from mGluR5 KO mice 
are histologically indistinguishable from WT littermates.	  The superficial, intermediate and basal 
epithelial cells are present (see Figure 3.1C and D) and the underlying mesenchyme and muscle 
layers also remain intact.  Furthermore, the barrier formed by the superficial cells is normal as 
evidenced by Uroplakin III staining (data not shown) in both the WT and mGluR5 KO mice. 
Therefore, the absence of mGluR5 affects the response to noxious bladder distention but does 
not alter gross urothelial architecture. 	  
 
Compensatory changes in gene expression represent a potential confound to any experiment 
utilizing genetic manipulation. Thus, the robust phenotype observed in the mGluR5 KO mice 
could be the result of compensatory expression changes in other genes that have a role in 
bladder nociception.  An acute pharmacological blockade of the receptor represents a potentially 
powerful approach to complement these findings from genetically modified mice. However, as 
mentioned above, the pharmacologic agent (MPEP) used in prior studies shows a clear lack of 
specificity in vivo (Montana et al., 2009).  To ask whether mGluR5 activation is acutely involved in 
distention-induced bladder nociception, we tested whether specific pharmacologic inhibition of 
mGluR5 with the selective antagonist fenobam (Zhu et al., 2004; Porter et al., 2005; Montana et 
al., 2009), would suppress the VMR to urinary bladder distention.  Systemic (intraperitoneal (IP)) 
administration of fenobam to WT mice resulted in a statistically significant reduction in the 
response to bladder distention compared to pretreatment baseline responses (Figure 3.2B, p< 
0.0001), whereas treatment with vehicle had no statistically significant effect on VMR compared 
to baseline (Figure 3.2A). Thus, pretreatment with fenobam mimicked the reduced nociceptive 
response to bladder distention that was observed in mGluR5 KO mice relative to their WT 
littermates (compare Figure 3.1A and 3.2A).  We next evaluated the effect of fenobam on the 
VMR of mGluR5 KO mice. Surprisingly, treatment with either vehicle (DMSO) or fenobam caused 
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a small but statistically significant decrease in the VMR evoked by bladder distention compared to 
baseline responses in mGluR5 KO mice (Figure 3.2C and D, p<0.001 and p=0.007).  
 
Figure 3.2: The selective mGluR5 antagonist, fenobam, is analgesic in distention-induced 
bladder pain model.  A. Treatment with the vehicle used to dissolve fenobam (100% DMSO) has 
no effect on the response to bladder distention. B. Treatment with an mGluR5 antagonist, 
fenobam, is analgesic in a bladder distention-evoked pain model. C&D. Fenobam and DMSO 
reduce the evoked response in mGluR5 KO mice. +/- SEM,* p<0.05, **p<0.01, ***p<0.001. 2-way 
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mGluR5 regulates intermicturition interval (IMI) To test the role of mGluR5 in urodynamics, we 
compared the cystometry profile of mGluR5 KO mice and their WT littermates. mGluR5 KO mice 
had a significantly increased IMI (212.3 seconds  versus  471.5 seconds, for WT and KO, 
respectively, p=0.0006) (Figure 3.3A-C). Despite the difference in IMI, the average amplitude of 
bladder contractions was not significantly different in mGluR5 KO mice relative to their WT 
littermates (Figure 3.3D, p=0.9215).  
 
Figure 3.3: mGluR5 KO mice have an increased intermicturition interval. A. Representative 
urodynamic profile of a WT mouse.  B. Representative urodynamic profile of a mGluR5 KO 
mouse.  A-C. The IMI in WT mice was significantly smaller when compared to mGluR5 KO mice 
(WT baseline IMI 212.3 ± 12.94 N=3, mGluR5 KO IMI baseline 471.5 ± 29.14 N=5). D. However, 
there was no difference in the bladder contraction amplitude. ***P<0.001 unpaired Student’s t-test 
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To determine if the voiding behavior we observed in mGluR5 KO mice was the result of genetic 
ablation of mGluR5 or the result of compensatory changes, we acutely treated WT mice with 
fenobam or vehicle and measured the effect on urodynamics.  While vehicle treatment had no 
effect on IMI (160.2 seconds versus 177.1 seconds, for baseline and vehicle (DMSO) 
respectively, p=0.66, Figure 3.4D), fenobam treatment increased the IMI when compared to the 
baseline IMI.  The IMI before fenobam treatment was 182 seconds (n=8). After IP fenobam 
treatment, four of the eight mice stopped bladder cycling and micturition immediately (Figure 
3.4C), while four of the mice had significantly increased IMI (481.3 seconds, p=0.031, Figure 
3.4D and E). The mean time to resume bladder cycling and micturition after systemic fenobam 
administration was 18.6 minutes. This suggests a tight coupling between mGluR5 activation and 
micturition cycling. The acute effect of the mGluR5 antagonist also suggests that the increased 
IMI observed in mGluR5 KO mice is not likely due to developmental changes as a result of 
genetic ablation of mGluR5.  
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Figure 3.4: Fenobam treatment increases the intermicturition interval. A-C. Representative 
urodynamic profile of WT mice before and after treatment.  An intraperitoneal (IP) injection with 
fenobam significantly increased the IMI in 4/8 mice treated (B,E), while 4/8 mice stopped cycling 
(C). In the mice that stopped cycling, the mean time to resume bladder cycling and micturition 
after IP fenobam administration was 18.6 ± 5.0 minutes. The IMI was not significantly affected by 
IP DMSO (n=7) (A,D).  *P<0.05 paired Student’s t-test compared to baseline.  
 
UPEC infection results in changes in bladder histology and an increased VMR Our results, 
together with previous studies (Guarneri et al.; Hu et al.; Larson et al.) suggest that mGluR5 is 
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bladder distention; however, the role of mGluR5 in inflammatory bladder nociception is 
unexplored.  We therefore used the UPEC model of bladder inflammation to examine the role of 
mGluR5 in inflammatory bladder nociception.  We found that UPEC infection resulted in an 
increased VMR to noxious bladder distention when compared to mock-infected littermate controls 
(Figure 3.5A, p< 0.0001).  Furthermore, in mice whose bladders had been distended, UPEC 
infection produced an increased infiltration of polymorphonuclear leukocytes observed throughout 
the full thickness of the bladder tissue (Figure 3.5B, arrowheads), as well as an increased tissue 
thickness of both the urothelium and mesenchyme compared to distended mock-infected mice 
(Figure 3.5C).  Noxious bladder distention combined with UPEC infection resulted in greater 
histological damage as measured by tissue inflammation scores when compared to mock-
infected mice with noxious distention (data not shown) (Hopkins et al., 1998).  UPEC infection 
(alone and with distention) resulted in barrier disruption through a loss of superficial facet cells, 
while noxious distention alone had no effect on these cells and the barrier remained intact 
(arrows, Figure 3.5C).  
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Figure 3.5: UPEC Infection results in histological 
changes and bladder hyperalgesia. A. 24 hour 
infection with uropathogenic E. coli (UPEC) increases 
the VMR to bladder distention when compared to 
mock-infected (PBS) littermates. B. Infection with 
UPEC results in an increased infiltration of 
polymorphonuclear leukocytes (arrowheads), and a 
sloughing of the superficial facet cells. C. Distention 
alone does not result in the loss of superficial facet 
cells (arrows,). +/- SEM *p<0.05, **p<0.01, 








mGluR5 is necessary for the full expression of inflammatory bladder nociception In mice with a 
UPEC-induced UTI, mice treated with vehicle had an increased VMR when compared to baseline 
(Figure 3.6A, p=0.0007). While vehicle treatment increased the VMR, treatment with fenobam 
resulted in a significantly reduced VMR when compared to pre-fenobam measurements (Figure 
3.6B, p=0.0006). In contrast, vehicle had no effect on the VMR in mice mock infected (with PBS 
instead of UPEC, Figure 3.6C).  In these control mice (mock infected), treatment with fenobam 
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3.6D). These results are consistent with those observed in WT mice (not mock-infected, Figures 
3.2A and 3.2B).   
 
Figure 3.6: A. Treatment with an mGluR5 antagonist, fenobam, is analgesic in a UPEC infection-
induced inflammatory bladder distention-evoked pain model (n=7). B. Treatment with the vehicle 
used to dissolve fenobam (100% DMSO) increases the evoked response to bladder distention 
(n=5). C. Fenobam is analgesic in mice given intravesicular PBS (control) 24 hr prior to VMR 
testing (n=6). D. Treatment with the vehicle used to dissolve fenobam (100% DMSO) had no 
effect on mice treated with intravesicular PBS (control, n=6), +/- SEM,* p<0.05, **p<0.01, 
***p<0.001. Paired 2-way ANOVA with Bonferroni post-hoc test. 
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DISCUSSION 
 
Clinically, visceral pain is often treated as a variant of somatic pain under the assumption that one 
neurological mechanism may be responsible for both visceral and somatic pain (Cervero and 
Laird, 1999). However, conventional treatments for somatic pain are often ineffective in treating 
visceral pain, indicating significant differences between visceral and somatic pain (Cervero and 
Laird, 1999; Robinson and Gebhart, 2008).  This is likely due, in part, to intrinsic differences 
between visceral nociceptors and non-visceral nociceptors (Reviewed in: (Gebhart, 2000, 2004; 
Robinson and Gebhart, 2008)). Our results support this difference as we found that blocking 
mGluR5 activation resulted in a decreased VMR in the absence of injury.  Whereas previous work 
has demonstrated that blocking mGluR5 activation has no effect on somatic pain in the absence 
of injury (Montana et al.; Kolber et al.).   
 
Although the role of mGluR5 in inflammatory bladder pain is unclear, a few reports have shown 
that mGluR5 antagonism can lead to analgesia in visceral pain models (acetic acid writhing and 
colonic distention) (Walker et al., 2001b; Walker et al., 2001a; Fisher et al., 2002; Hudson et al., 
2002; Varner, 2002; Zhu et al., 2004; Lindstrom et al., 2008; Hu et al., 2009). A recent publication 
reported that an mGluR5 antagonist, MPEP, effectively reduced the nociceptive VMR to noxious 
distention of non-inflamed bladders in rats (Hu et al., 2009).  However, MPEP, has since been 
shown to have off-target effects, as it retains analgesic efficacy in mGluR5 KO mice (Montana et 
al., 2009). Thus, the precise role of mGluR5 in bladder distention-induced nociception remains 
unclear.  Further, it is unknown whether mGluR5 activation has a role in the more clinically 
relevant condition of inflammatory bladder pain. In the present study, we demonstrate that 
mGluR5 is necessary for the full expression of distention-induced bladder nociception in naïve as 
well as UPEC-infected mice.   
 Here, we demonstrate the importance of mGluR5 in non-inflammatory bladder nociception using 
both genetic and pharmacologic techniques. First, mice lacking mGluR5 have a significantly 
reduced response to noxious bladder distention when compared to their WT littermates. Despite 
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this dramatic effect, mGluR5 KO mice have no baseline motor deficiencies (Lu et al., 1997). 
However, genetic deletion of mGluR5 could result in unpredictable upregulation or compensation 
of other genes involved in bladder function.  Acute systemic treatment with a selective mGluR5 
antagonist (fenobam) mimics the blunted VMR observed in the mGluR5 KO mice, suggesting that 
the absence of mGluR5 activity accounts for the differences in VMR as well as the cystometric 
profile observed in mGluR5 KO mice. Together these data suggest that mGluR5 is necessary for 
the full expression of distention-induced bladder pain in naïve mice and highlight the therapeutic 
potential for mGluR5 antagonists in the treatment of bladder pain.  
 
Surprisingly, both fenobam and vehicle (DMSO) induced a small but statistically significant 
reduction in the distention induced VMR in mGluR5 KO mice.  Fenobam at the dose used in this 
study was previously demonstrated to be specific to mGluR5 in vivo (Montana et al., 2009), and 
we do not believe that these results challenge that finding because fenobam but not DMSO, had 
an effect on the VMR of WT mice.  Because both fenobam and vehicle significantly reduced the 
VMR in mGluR5 KO mice, we conclude that the vehicle is having effects in the KO that are not 
observed in WT mice.  A possible explanation for the effects of the DMSO in KO but not in WT 
mice is that mGluR5 KO mice are significantly smaller than their WT littermates (Bradbury et al., 
2005). DMSO has been shown to block peripheral C-fiber nerve conduction (Evans et al., 1993). 
It is possible that the volume (20µl) delivered in relation to the weight of the mGluR5 KO mice 
leads to such a conduction block.   
 
The dramatic phenotype of mGluR5 KO mice as well as the significantly reduced pain response 
in fenobam-treated WT mice suggests that mGluR5 regulates bladder nociception.  It is also 
possible that mGluR5 could regulate normal bladder function such as micturition. To examine the 
role of mGluR5 in normal bladder function, we examined the cystometric profiles of mGluR5 KO 
mice compared to their WT littermates. Genetic disruption of mGluR5 significantly increased the 
IMI, but had no effect on the bladder contraction amplitude (pressure at which voiding occurred).  
An increased IMI suggests that mice lacking mGluR5 are able to urinate, but they tolerate higher 
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bladder volumes (i.e. higher bladder distension) before voiding. Our results are consistent with 
previous work demonstrating a role for mGluR5 in the micturition reflex (Guarneri et al., 2008; Hu 
et al., 2009; Larson et al., 2011). Importantly, mGluR5 does not appear to be involved in bladder 
development, as bladders of mGluR5 KO mice were indistinguishable from their WT littermates 
upon gross inspection. These results suggest that mGluR5 has a role in bladder sensation in 
naïve mice.  
 
Bladder infections due to UPEC are the most common reason that women see a doctor 
(Baerheim and Hunskar, 1997; Hooton and Stamm, 1997).  This is the first evidence that infection 
with UPEC sensitizes mice to noxious bladder distention.  WT mice infected with UPEC had a 
greater VMR to bladder distention when compared to mock-infected littermate controls. These 
data are consistent with the finding that mice with a UTI have increased referred abdominal pain 
(Rudick et al.).  Furthermore, our results indicate that pharmacologic blockade of mGluR5 
activation can reduce the VMR to bladder distention in UPEC-infected mice. The reduction in the 
distention-evoked VMR after fenobam treatment in mice infected with UPEC may be even larger 
than is apparent in Figure 6B, as the VMR is actually increased in vehicle-treated mice (see Fig 
3.6A). Because distention in combination with UPEC infection was more damaging to bladder 
histology than distention in mock infected mice, the increased VMR after vehicle is likely the 
result of injury induced by bladder infection in combination with repeated noxious bladder 
distention. Another, yet unlikely, explanation is that systemic DMSO might lead to bladder 
sensitization in mice with UPEC infection.   
Models of somatic inflammatory pain have observed an increase in mGluR5 CNS expression 
(specifically the central nucleus of the amygdala and the spinal cord) following peripheral 
inflammation (Dolan et al.; Neugebauer et al.).  However, it remains undetermined if visceral 
inflammation leads to increased expression of mGluR5. 
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CONCLUSIONS 
Up to 85% of community-acquired UTIs are due to infection with UPEC (Foxman and Brown, 
2003; Zhang and Foxman, 2003). Standard-of-care for a UTI is antibiotic treatment.  However, in 
women with normal urological anatomy (uncomplicated UTI), UTIs are self-limiting (Foxman, 
2010). Therefore, uncomplicated UTIs will resolve without antibiotic treatment.  Despite this, the 
pain due to a UTI necessitates antibiotic treatment for symptomatic relief.  Antibiotic use can lead 
to UTI recurrence by selecting for antibiotic resistant bacteria (Foxman, 2010). By treating the 
pain of a UTI rather than the infection, it may be possible to allow the UTI to take its natural 
course and become self-limited and reduce antibiotic-resistant reoccurrence.  Based on our 
findings, we suggest that mGluR5 antagonists could be a useful for therapy for symptomology in 
UTI that could reduce antibiotic use. 
Although less common, bladder pain in the form of IC/PBS is a serious and debilitating medical 
condition.  Unfortunately for patients, no reliably effective treatment options exist. Previous work 
has suggested a role for mGluR5 in the CNS in distention-induced bladder pain (Hu et al.).  
However, the mGluR5 antagonist used in this study (MPEP) is analgesic in mGluR5 KO mice, 
suggesting off-target effects (Montana et al.).  Here, using a combination of genetics and 
pharmacology, we demonstrate that mGluR5 has a crucial role in the modulation of distention 
induced bladder nociceptive responses.  Because in these studies mGluR5 was blocked 
systemically and knocked out globally, the anatomical localization where mGluR5 modulates 
bladder pain is undefined.  In addition, mGluR5 is expressed throughout the peripheral and 
central nervous system (Valerio et al.; Jia et al.; Karim et al.; Varney and Gereau; Li and 
Neugebauer; Ferraguti and Shigemoto; Kolber et al.).  However, it should be noted that the 
mGluR5 antagonist, fenobam, readily and rapidly crosses the blood brain barrier (Montana et al.). 
If the chronic pain experienced due to IC/PBS is also mediated by mGluR5, then antagonists of 
mGluR5 such as fenobam may be useful in treating chronic bladder pain.  Antagonists of mGluR5 
may have clinical potential for the treatment of both acute and chronic bladder pain. Previous 
work using non-visceral pain models has demonstrated that mGluR5 activity modulates the 
activation of ERK1/2 (extracellular regulated kinase 1/2) in both the spinal cord (Karim et al.; Hu 
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et al.) and/or central nucleus of the amygdala (CeA) (Kolber et al.; Li et al., 2011).  Inhibition of 
mGluR5 in the CeA is analgesic in multiple models of somatic inflammatory pain (Li and 
Neugebauer; Kolber et al.). Furthermore, recent work from our lab has demonstrated that 
intrathecal inhibition of ERK is analgesic in both an inflammatory and non-inflammatory bladder 
pain model (Lai et al.).  Future work can help determine the anatomical and molecular 
mechanism by which mGluR5 modulates bladder nociceptive responses. 
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METHODS 
1. Subjects and ethical approval 
All animal experiments were performed in accordance with the guidelines of the Committee for 
research and Ethical Issues of International Association for the Study of Pain (Zimmermann, 
1983). The experimental protocol was approved by the Washington University Institutional Animal 
Care and Use Committee (St. Louis, MO). All experiments were performed on female mice aged 
10-13 weeks. All mice were humanely euthanized at the end of the experiments by decapitation 
under deep isoflurane (5%) anesthesia. Female C57BL/6 mice used in UPEC experiments were 
purchased from The Jackson Laboratory (Bar Harbor, ME). For experiments involving mice 
lacking mGluR5 (mGluR5 KO), animals were bred in-house on a C57BL/6 background and 
compared with wildtype (WT) littermates (Lu et al., 1997). Unless otherwise indicated, all mice 
were group housed in cages of 3-5.  All mice were kept on a 12:12-h light/dark schedule with ad 
libitum access to food and water.  
2. Drugs and other agents 
Fenobam was purchased from Tocris Bioscience (Ellisville, MO), and is a specific negative 
allosteric modulator of mGluR5 (Porter et al., 2005; Montana et al., 2009). The dosage (30mg/kg, 
intraperitoneal) of fenobam was chosen because it was the lowest effective dose to induce 
analgesia in two mouse models of inflammatory pain, and had no effect on mGluR5 KO mice 
(Montana et al., 2009). Fenobam was dissolved in 100% dimethyl sulfoxide (DMSO, Sigma-
Aldrich, St. Louis, MO) on the day of the experiment. All intraperitoneal injections were 20µl.  
Throughout all experiments and analysis, the investigator performing the VMR was blinded to 
pharmacological treatment.  
3. Phasic bladder distentions and VMR measurements 
Visceral nociception was quantified using VMR, an electromyographic (EMG) recording of the 
abdominal muscle response to bladder distention that has previously been validated as a 
measure of nociception (Ness and Gebhart, 1991; Ness and Elhefni, 2004). An example of the 
bladder-distention induced VMR of WT mice can be seen in Figure 1. Abdominal VMRs to urinary 
	   73 
bladder distention were performed as described previously (Lai et al., 2011). The mice were 
anesthetized with 2% isoflurane, and chlorinated silver wire electrodes were placed on the 
superior oblique abdominal muscle. One was placed subcutaneously across the abdominal wall 
(as a ground) to allow differential amplification of the abdominal VMR signals. A lubricated 24G 
angiocatheter was inserted into the bladder via the urethra for bladder distention. After completion 
of the surgical preparation, isoflurane anesthesia was reduced to approximately 0.9% until a 
flexion reflex response was present (evoked by pinching the paw) but spontaneous escape 
behavior and righting reflex were absent. Once a stable depth of anesthesia was obtained, the 
level was not changed for the duration of the experiment. The animals were not restrained in any 
fashion. Body temperature was monitored throughout the experiment and maintained using an 
overhead radiant light. Phasic bladder distention with compressed air was then used to evoke a 
VMR. The air pressure was controlled by an automated distention control device custom made in 
the Washington University School of Medicine Electronics Shop. The distention stimulus applied 
20 to 80 mm Hg pressure (10mmHg steps) for 20 seconds every 2 minutes. The VMR signal was 
relayed in real time using a Grass CP511 preamplifier (Grass Technologies, West Warwick, RI) to 
a PC via WinDaq DI-720 module (Dataq Instruments, Arkon, OH). These data were exported to 
Igor Pro 6.05 software (Wavemetrics, Portland, OR). Using a custom script, the VMR signals 
were subtracted from the baseline, rectified, and integrated over 20 seconds to quantify the area 
under the curve (see Figure 1). The VMR is presented in arbitrary units.  
After baseline responses to distensions 20mmHg-80mmHG (10mmHg steps) were recorded, the 
mouse was allowed to recover for at least 30 min (level of anesthesia remained unchanged). 
Following baseline recordings, the mice were given a 20ul IP injection of either fenobam 
(30mg/kg, dissolved in 100% DMSO) or 100% DMSO (vehicle). A second set of bladder 
distentions (20mmHg-80mmHg, 10mmHg steps) was started 5 minutes following administration 
of fenobam or vehicle and completed within 45 minutes. The investigator who tested, processed 
and quantified the VMR was blinded to the drug treatment and genotype.	  
4. Infection with UPEC 
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Infection with a clinical UPEC isolate, UTI89, was performed as previously described (Hung et al., 
2009). Briefly, mice were anesthetized with isoflurane and inoculated via transurethral 
catheterization with 50 µl of 2-8x107 colony-forming units/mL of bacteria in phosphate buffered 
saline (PBS). Control mice (mock-infection) received 50ul of intravesicular PBS. Following 
intravesicular instillation of either PBS or UPEC, the mice were individually housed. Urine was 
collected at 6 and 24 hours, and infection was confirmed. At 24 hours post infection, the VMR 
response to bladder distention was recorded as previously described (Lai et al., 2011). Following 
the VMR, isoflurane anesthesia was increased and the mice were euthanized by cervical 
dislocation. Bladder tissue was quickly removed and fixed in methacarn (60% methanol, 30% 
chloroform, 10% glacial acetic acid) (Mysorekar and Hultgren, 2006). The bladder tissue was then 
embedded in paraffin, sectioned and stained with hemotoxylin and eosin.  Photomicrographs 
were taken using a Hamamatsu NanoZoomer HT (Hamamatsu Corporation).  
5. Urodynamics 
Urodynamic recordings were performed as described previously (Lai et al., 2004).  Briefly, mice 
were anesthetized with subcutaneous urethane (1.2g/kg). A midline laparotomy incision was 
made, and the dome of the urinary bladder was exposed. The bladder dome was punctured with 
a 25-gauge needle.  Intravesicular pressure was monitored continuously in vivo while the bladder 
was filled with room temperature saline at a rate of 0.04 mL per minute using a syringe pump (KD 
Scientific, New Hope, PA). Voiding was allowed to occur spontaneously via the urethra.  The 
intravesicular pressure was recorded in real time using WINDAQ data acquisition program 
(DataQ Instruments, Akron, OH) at a sampling rate of 20 Hz. The intermicturition interval (IMI) 
was calculated as the average time (seconds) between peaks. The amplitude of contraction was 
the value (cmHg) of the peak.  
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LIST OF ABBREVIATIONS 
DMSO, dimethyl sulfoxide; IC/PBS, Interstitial cystitis/painful bladder syndrome; IMI, 
intermicturition interval; IP, intraperitoneal; KO, knockout; mGluRs, metabotropic glutamate 
receptors; mGluR5, metabotropic glutamate receptor 5; MPEP, 2-methyl-6-(phenylethynyl)-
pyridine; PBS, phosphate-buffered saline; UPEC, uropathogenic Escherichia Coli; UTI, urinary 
tract infection; VMR, visceromotor response; WT, wildtype 
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ABSTRACT 
Painful bladder syndrome is a debilitating condition that affects 3-6% of women in the United 
States. Multiple lines of evidence suggest that changes in central nervous system processing are 
key to the development of chronic bladder pain conditions, but little is known regarding the 
underlying cellular, molecular, and neuronal mechanisms. Using a mouse model of distension-
induced bladder pain, we found that the central nucleus of the amygdala (CeA) is a critical site of 
neuromodulation for processing of bladder nociception.  Furthermore, we demonstrate that 
metabotropic glutamate receptor 5 (mGluR5) activation in the CeA induces bladder pain 
sensitization by increasing CeA output.  Thus, pharmacological activation of mGluR5 in the CeA 
is sufficient to increase the response to bladder distension.  Additionally, pharmacological 
blockade or virally-mediated conditional deletion of mGluR5 in the CeA reduced responses to 
bladder distention suggesting that mGluR5 in the CeA is also necessary for these responses.  
Finally, we used optogenetic activation of the CeA and demonstrated that this caused a robust 
increase in the visceral pain response.  The CeA localized effects on responses to bladder 
distention are associated with changes in extracellular signal regulated kinases 1/2 
phosphorylation in the spinal cord.  Overall, these data demonstrate that mGluR5 activation leads 
to increased CeA output that drives bladder pain sensitization.  
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INTRODUCTION   
Visceral pain is the most common reason that patients seek medical attention and the most 
common form of pain produced by disease (Cervero and Laird, 1999). Visceral pain associated 
with interstitial cystitis or painful bladder syndrome (PBS/IC) affects 3-8 million women in the US 
(Berry et al., 2011), yet PBS/IC is poorly understood and treated (Dimitrakov et al., 2007). Up to 
91% of these patients carry a diagnosis of another chronic disorder such as chronic fatigue, 
migraine, fibromyalgia, anxiety, and/or depression (Warren et al., 2009).  Factors such as stress 
and depression (Macaulay et al., 1987; Baldoni et al., 1995) increase PBS/IC pain, and chronic 
pain is associated with increases in both stress and depression. Activity in the amygdala, a 
primary limbic structure, is positively correlated with stress, anxiety, and pain behavior 
(Neugebauer et al., 2004; Carrasquillo and Gereau, 2007; Ikeda et al., 2007; Ji et al., 2007; 
Neugebauer, 2007).  The fact that emotion and stress modulate visceral pain and that the 
amygdala processes stress and nociceptive signals suggests that the amygdala is involved in the 
pathogenesis of chronic visceral pain.   
The central nucleus of the amygdala (CeA) receives both indirect and direct nociceptive 
information (Bernard and Besson, 1990; Burstein and Potrebic, 1993; Bernard et al., 1996; 
Bourgeais et al., 2001).  Noxious colorectal distension increases c-fos expression in the CeA 
(Traub et al., 1996) and the excitability of CeA neurons increases after induction of colitis in rats 
(Han and Neugebauer, 2004).  Afferent outputs from the CeA to the hypothalamus and brainstem 
regions such as the periaqueductal gray (PAG) also make the amygdala well positioned to 
modulate responses to painful stimuli.  Activation of the CeA with chronic corticosterone implants 
increases visceromotor responses to distension in rats (Greenwood-Van Meerveld et al., 2001; 
Myers and Greenwood-Van Meerveld, 2010).  However, it is undetermined if acute changes in 
excitability of CeA neurons modulate the response to noxious bladder stimulation.  
The excitability of neurons in the CeA during visceral stimulation is modulated in part by 
metabotropic glutamate receptor 5 (mGluR5) (Li and Neugebauer, 2004). mGluR5 activation of 
extracellular signal regulated kinases 1/2 (ERK1/2) has been hypothesized to play a role in the 
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modulation of pain responses (Ji, 2004; Kolber et al., 2010). Pharmacological activation of 
mGluR5 in the CeA increases rectal distension-induced neuronal responses (Ji and Neugebauer, 
2010) and behavioral vocalizations (Li et al., 2011).  However, it is unknown whether mGluR5 in 
the CeA plays a key role in bladder pain.   
Here, we used right amygdala-specific pharmacological activation and inhibition of 
mGluR5 as well as conditional deletion of mGluR5 to determine the role of CeA-specific mGluR5 
signaling in bladder pain.  Next, we used optogenetic approaches to stimulate CeA neurons to 
determine if increased activation of the CeA neurons increases the visceromotor response to 
noxious bladder distention. Overall, we demonstrate that either mGluR5 activation in the CeA or 
optogenetic activation of the CeA is sufficient to sensitize responses to painful bladder distention; 
we have identified a novel role for mGluR5 in the ongoing control of acute visceral pain.   
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MATERIALS AND METHODS  
Animals. 
All mouse protocols were in accordance with National Institutes of Health guidelines and were 
approved by the Animal Care and Use Committee of Washington University (St. Louis, MO) and 
Duquesne University (Pittsburgh, PA). Female mice (all C57Bl/6J background) age 10-13 weeks 
old were housed on a 12/12 h light/dark schedule with ad libitum access to rodent chow and 
water.   Unless otherwise noted, wildtype (WT) mice were used for all experiments. 
Visceromotor response (VMR) to urinary bladder distention. 
The VMR is a spinobulbospinal reflex to bladder distention that has been validated as a measure 
of pain, as the response is suppressed by analgesics and potentiated by bladder inflammation.  
The VMR is observed in decerebrate rodents and not in rodents with a transected spinal cord 
(Castroman and Ness, 2001; Ness et al., 2001; Ness and Elhefni, 2004) but can also be 
modulated by higher brain centers (Qin et al., 2003).  Bladder distention reliably produces pain 
and/or discomfort in humans (Ness et al., 1998) and is frequently used in rodents as a model of 
visceral pain.  Procedures for bladder distention and visceromotor response (VMR) recording 
were similar to those previously described (Lai et al., 2011) (see Fig. 4.1A for illustration of 
setup).  Experimenter was blinded to treatment and/or genotype in all experiments.  Briefly, on 
the day of VMR recording, the mice were anesthetized with 2% isoflurane.  Chlorinated silver wire 
electrodes were placed on the external oblique abdominal muscle and subcutaneously across the 
abdominal wall (as a ground) to allow differential amplification of the abdominal VMR signals.  A 
lubricated angiocatheter was inserted into the bladder via the urethra for bladder distention.  After 
surgical preparation, isoflurane was reduced to approximately 1.0% until a flexion reflex response 
was present (evoked by pinching the paw) but spontaneous escape behavior and righting reflex 
were absent.  The use of low levels of isoflurane during UBD has been validated previously (Ness 
and Elhefni, 2004).  After the desired level of anesthesia was achieved, the level of isoflurane 
was not changed for the duration of the experiment.  The animals were not restrained in any 
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fashion and body temperature was maintained using an overhead radiant light and monitored 
throughout the experiment.   Phasic bladder distention with compressed air was then used to 
evoke bladder nociception.  The air pressure was controlled by an automated distention control 
device custom made in the Washington University School of Medicine Electronic Shop (St. Louis, 
MO).  The distention stimulus applied was 20 to 80 mmHg pressure for 20s with 2min inter-trial 
interval (ITI). The precise pressure gradient used varied depending on the specific experiment 
(see Results).    The VMR signal was relayed in real time using a Grass CP511 preamplifier 
(Grass Technologies, West Warwic, RI) to a PC via a WinDaq DI-720 module (Dataq 
Instruments, Akron, OH).  Data were exported to Igor Pro 6.05 software (Wavemetrics, Portland, 
OR).  Using a custom script, the VMR signals were subtracted from the baseline, rectified, and 
integrated over 20s to quantify the evoked response.    
Surgical procedure for cannula implantation. 
WT mice were cannulated as previously described (Kolber et al., 2010). Briefly, mice were deeply 
anesthetized with a combination ketamine/xylazine anesthetic and mounted in a stereotaxic 
frame.  An 8mm stainless steel guide cannula was implanted above the right CeA (coordinates: 
1.25mm anterior to Bregma; 2.70mm lateral to midline; 4.2mm ventral to skull). The guide 
cannula was affixed to the skull with two bone screws and dental cement. An 8mm stylet was 
inserted in the guide cannula to prevent clogging. Mice recovered for 3d (for HSV optogenetic 
experiments) or 6d (for pharmacological experiments) before further testing. At the end of 
experiments, brains were sectioned to verify cannula position and injection site.   Briefly, for all 
experiments, the cannula end was verified by histological or visual analysis (under 4x 
magnification).  This included first using a mouse stereotaxic atlas (Paxinos and Franklin, 2001) 
and the hippocampus as a rostral-caudal guide to identify the brain section corresponding to the 
tip of the cannula.  Next, a determination of correct CeA targeting was done by using the internal 
branch of the external capsule and the optic tract as markers for the lateral and medial aspects of 
the CeA.  The center of the cannula target was verified by looking at serial sections across the 
extent of the cannulated area.  For Western experiments in which only 1mm sections were 
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analyzed, the section was cut directly over the cannula tract and punches were made on either 
side of the cannula tip after visual verification of CeA targeting.  For experiments described in this 
manuscript, we have included insets in figures that show cannula tip placements.   In all 
experiments, the right amygdala only was targeted for manipulation because previous results 
from both mice (Carrasquillo and Gereau, 2008; Kolber et al., 2010) and rats (Ji and Neugebauer, 
2009; Li et al., 2011) have shown a specific lateralization of the right amygdala in somatic and 
visceral pain. 
Intra-amygdala drug infusion 
Mice were cannulated targeting the right amygdala as described above.  6d after cannulation 
surgery, drugs were infused.  Microinjections were performed as previously described 
(Carrasquillo and Gereau, 2007).  Briefly, injections were performed using a 32-gauge injection 
cannula that extended 0.5mm beyond the tip of the guide cannula. The injection cannula was 
attached to flexible plastic tubing and a microliter syringe (Hamilton, Reno, NV) was used to 
deliver drug or vehicle. A total volume of 0.3mL was infused over a period of 3min and the 
injection cannula was kept in place for an additional 1min to allow for drug diffusion.   
   Drugs Injected. (RS)-3,5-Dihydroxyphenylglycine (DHPG) (Tocris, Bristol, UK) is an 
agonist that activates both mGluR5 and mGluR1. On the day of the experiment, DHPG was 
dissolved in artificial cerebrospinal fluid (aCSF; 25mM NaHCO3, 122mM NaCl, 1.3mM CaCl2, 
1.2mM MgSO4, 3mM KCl, and 0.4mM KH2PO4, pH 7.35) as a 5mM stock solution, which was 
diluted in aCSF to 0.1nmol (final injected volume 0.3ml). Mice were treated with DHPG 30min 
following baseline distention and then distended again 30min after treatment.  2-Methyl-6-
(phenylethynyl)pyridine hydrochloride (MPEP, Tocris) is a selective non-competitive antagonist of 
mGluR5.  On the day of the experiment, MPEP was dissolved in aCSF a stock 5mM solution, 
which was diluted in aCSF to a final concentration of 0.01 nmol (final injected volume 0.3ml). For 
bladder distention experiments with baseline distention, mice were treated with MPEP (or vehicle) 
immediately following baseline distention and then distended again 60min after treatment.  For 
bladder distention experiments with no baseline distention, mice were treated with MPEP (or 
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vehicle) 60min prior to bladder distention at 80 mmHg.  Dosing and timing for DHPG and MPEP 
was derived from our previous studies examining amygdala-induced somatic hypersensitivity 
(Kolber et al., 2010).    
Preparation of CeA specific mGluR5 knockout mice (mGluR5CeAKO).   
Mice homozygous for the mGluR5loxP allele (Xu et al., 2009) or WT littermates were used. All 
animals were injected in the right amygdala with virus containing recombinant lentiviral vector LV-
Ef1α-Cre (LV-Cre) as previously described (Kolber et al., 2008; Kolber et al., 2010). Briefly, mice 
were anesthetized with a combination ketamine/xylazine anesthetic and mounted in a stereotaxic 
frame. A small hole was drilled over the right CeA (coordinates: 1.25mm anterior to Bregma; 
2.7mm lateral to midline; 4.7mm ventral to skull).  A 32-Gauge needle was lowered into the hole 
and 4x105 infectious viral particles were injected over 5min.  The injection needle was kept in 
place after injection for 4min to allow for stable diffusion. All testing in these mice occurred 2 
weeks after recovery from surgery. After testing, brains were sectioned to determine needle 
targeting and 1mm diameter x 1mm high punches were made of the amygdala in two adjacent 
sections to determine amount of mGluR5 protein disrupted in mGluR5CeAKO mice compared to WT 
mice injected with LV-Cre.  In addition, tissue from the lumbosacral spinal cord was harvested for 
analysis of ERK phosphorylation.  See below for a description of processing of tissue samples.    
Optogenetic vectors, infusion, and stimulation parameters. 
Vectors. Herpes simplex virus (HSV) vectors were obtained from McGovern Institute 
(MIT, Boston, MA).  Briefly, HSV vectors driven by the CMV promoter (channelrhodopsin 
hChR2(H134R)-EYFP or EYFP only) were prepared as previously described (Neve et al., 2005; 
Covington et al., 2010).   All experiments were performed on day 4 after postinfection because 
maximal expression of HSV vectors occurs on days 3-4 (Covington et al., 2010).   
Vector infusion.   Mice were cannulated in the right amygdala as described above.  3d 
after cannulation surgery, HSV vectors were infused.  Microinjections were performed similarly to 
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that described above for drugs. A total volume of 1mL was infused over a period of 5min and the 
injection cannula was kept in place for an additional 1min to allow for viral infusion.    
 Optogenetic CeA stimulation during bladder distention.  On the day of the experiment, an 
8.00mm fiber optic fiber (0.2 mm diameter; Thor Labs, Newton, New Jersey) was placed in the 
animal’s cannula.   Optic stimulation was performed similar to previously published protocols 
(Covington et al., 2010; Zhang et al., 2010).  Briefly, the fiber optic was connected via a FC/PC 
adaptor to a 473nm blue laser diode (OEM East Lansing, MI) connected to a power supply.  
Laser pulses were controlled using a Techtronix pulse generator.   During all stimulations, a 5ms 
20Hz (18ms spike width) pulse train was delivered for 30min.  The stimulation protocol was 
modeled to mimic the firing pattern of CeA neurons that occurs after painful injury in rodents (Ji 
and Neugebauer, 2009).   The intensity of the fiber optic light was verified before and after each 
experiment use using a luxometer (Thor Labs).   For the distention experiment, we applied a 
bladder stimulus of 30 mmHg (20s x3 with 2min ITI) then 60 mmHg (20s x3 with 2min ITI) during 
baseline testing, 20 min after the laser was turned on, and 15 min after the laser was turned off.  
For Western blot and immunohistochemistry experiments, mice were stimulated with the laser as 
above for 30min and then killed 15min after laser off with no distention.   Mice were killed after the 
experiment and analyzed by immunohistochemistry and western blotting for targeting, ERK 
phosphorylation, and/or eYFP expression (see below). 
Western Blotting. 
Protein expression in mGluR5CeAKO mice. After bladder distention (see above), spinal 
cords were removed by hydraulic extrusion from mGluR5CeAKO mice (compared to LV-Cre injected 
WT mice).  The lumbosacral portion of the spinal cord that is innervated by bladder afferent input 
(L6-S1) was isolated by (1) identifying the thickest portion of the lumbar enlargement as L4/L5, 
(2) measuring 2mm caudal to this portion as the start of L6, and then (3) isolating a section of 
cord that started at this L6 point and continuing 7mm caudal.  This method of identification has 
been validated by our immunohistochemical analysis of pERK1/2 in the dorsal horn after bladder 
distention (Lai et al., 2011).  That is, the Western “lumbosacral” isolates used in this experiment 
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correspond to the immunohistochemical sections that stain positive for phosphorylated ERK1/2 
after bladder distention.  After the lumbosacral portion of the spinal cord was isolated, the tissue 
was frozen on dry ice.  Brains were removed, sectioned into 1-mm-thick coronal sections using 
an acrylic brain matrix (Stoelting) and amygdala punches (2 per side per animal) were obtained 
using a custom-made 1mm punch tool and frozen on dry ice.  All tissue samples were 
homogenized with ice-cold homogenization buffer (20mM Tris-HCl, pH7.4, 1mM EDTA, 1mM 
sodium pyrophosphate, 25mg/mL aprotinin, 25mg/mL leupeptin, and 100mM 
phenylmethylsulphonyl fluoride). The levels of mGluR5 in the left or right amygdala were 
measured by Western blotting using antibodies specific for mGluR5 and the loading control 
protein b-Tubulin.  Total protein (7.5mg) for amygdala homogenates was separated using 4-12% 
SDS-PAGE and transferred to nitrocellulose membranes. For mGluR5 Western blotting, 
membranes were blocked in Odyssey blocking buffer for 1h and then co-incubated in mouse anti-
b-Tubulin (1:10,000, Sigma) and rabbit anti-mGluR5 (1:1,000, Millipore, Billerica, MA) primary 
antibodies in Odyssey buffer with 0.1% Tween-20 for 1h at RT.  After washing in TBS with 0.1% 
Tween-20, blots were incubated in goat anti-mouse IR800 (1:20,000, Sigma) and goat anti-rabbit 
Alexa 680 (1:20,000, Sigma) for 1h at RT. Blots were washed and scanned using an Odyssey 
Infrared scanner. Densitometry of bands corresponding to mGluR5 and b-Tubulin was performed 
using Odyssey software (V3.0).  Each mGluR5 band was divided by the pixel value for that 
sample’s b-Tubulin value and then normalized to the left amygdala because our previous results 
showed that mGluR5 protein is increased in the right amygdala compared to the left amygdala 
(Kolber et al., 2010).  The levels of ERK1/2 phosphorylation in the spinal cord were measured by 
Western blotting using antibodies specific for phosphorylated ERK and for total ERK. Total 
protein (5mg) for spinal cord homogenates was run as described above.  Blots were blocked as 
above and then co-incubated in mouse anti-p44/42 ERK (1:1000, Cell Signaling, Beverly, MA) 
and rabbit antiphospho-p44/42 ERK (1:1000, Cell Signaling) primary antibodies in Odyssey buffer 
with 0.1% Tween-20 (Sigma) for 1h at RT. Final processing was done as above. Densitometry of 
bands corresponding to ERK1 (p44) and ERK2 (p42) was performed using Odyssey v3.0 
software (Licor).   
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Bladder distention induced ERK1/2 activation.  All mice (sham undistended and 
distended) were anesthetized and catheterized as described above for urinary bladder distention 
testing.  Distended animals received 20s 80 mmHg bladder distention stimulation (x5 with 2min 
ITI).   Mice were killed 5min after last bladder distention (or equivalent amount of time for sham 
mice).  Spinal cords and brains were processed as above.  Westerns were done as above on 
spinal cord and amygdala tissue for phosphorylated ERK and for total ERK.   
Optogenetically-induced spinal cord ERK1/2 phosphorylation.  Mice were anesthetized 
and catheterized as described above for urinary bladder distention testing.  All mice (HSV-EYFP 
and HSV-hChR2(H134R)-EYFP) received 30min of stimulation using the optical stimulation 
protocol described above.  15min following termination of optical stimulation, mice were killed, 
and spinal cord was processed as above.  Western blotting was completed using spinal cord 
tissue and assessing levels of phosphorylated ERK1/2 and total ERK1/2. 
Immunohistochemistry. 
YFP CeA expression. Following the optogenetic bladder stimulation experiment 
(described above), mice were deeply anesthetized with pentobarbital, perfused transcardially with 
PBS (37oC), followed by 25mL of ice-cold 4% paraformaldehyde (PFA) solution in PBS. The brain 
was dissected and postfixed in PFA overnight at 4oC. After cryoprotection in 30% sucrose, 
coronal sections (30mm) were obtained on a cryostat and stored in PBS at 4oC until 
immunostaining. Sections were rinsed in TBS and blocked in 1% BSA/0.2% milk/0.1% triton X for 
1h at RT.  Sections were incubated overnight at 4oC in rabbit anti-GFP antibody (1:2000, 
Invitrogen) in blocking solution. Sections were rinsed in TBS with 0.1% triton X-100 and incubated 
in donkey anti-rabbit Alexa 555 secondary antibody (1:250, Invitrogen) in blocking solution for 1h 
at RT.  Sections were rinsed in TBS with 0.2% triton X-100, TBS, and then wet mounted and 
visualized using a Nikon Eclipse80i fluorescent microscope.  
Optogenetically-induced spinal cord ERK1/2 phosphorylation. Following optogenetic CeA 
stimulation (described above), mice were deeply anesthetized with pentobarbital then perfused 
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with PBS (37°C) followed by ice cold 4% PFA. The spinal cord was removed and the L4-S2 
region was isolated. Samples were fixed in 4% PFA for 4h, followed by 30% sucrose for 48h, both 
at 4°C. 30µm transverse sections were cut on a cryostat then immediately placed in PBS. 
Representative sections from L6-S1 of the spinal cord were rinsed in PBS then placed in 1.0% 
sodium borohydride for 10 minutes. Following additional rinses, sections were washed in PBS 
with 0.1% Triton X-100 then rinsed again. Sections were blocked in 5% normal goat serum with 
PBS containing 0.1% Triton X-100, 1% BSA, and 0.1% fish gelatin at RT for 1h. Exposure to 
rabbit anti-pERK (1:200, Cell Signaling) occurred overnight at 4°C in 1.5% NGS blocking solution. 
Sections were rinsed in PBS then incubated with goat anti-rabbit Alexa Fluor488 antibody (1:200, 
Life Technologies) in 1.5% NGS blocking solution at RT for 1h. After a final rinse, sections were 
wet mounted and visualized using a Nikon Microphot-SA microscope. pERK was quantified in 4 
L6-S1 sections for each animal. For cell counts, each spinal cord section was divided into 4 main 
regions as previously established (Lai et al., 2011); deep dorsal commissure (DCM), spinal 
parasympathetic nuclei (SPN), lateral dorsal horn (LDH), and medial dorsal horn (MDH). The total 
number of cells in each region was counted for each section. For each animal, an average cell 
count was determined using the 4 sections so that presented data represent the average number 
of positive cells per section per mouse.  All spinal cords were removed and processed on the 
same day. Sections from all animals were stained at the same time. The researcher who 
performed the cell counts was blinded to the treatment groups.  
Data Analysis. 
Results are expressed as means + SEM. Student’s t-tests were used to compare pairs of means. 
In cases of two independent variables (e.g. genotype and pressure), 2-way ANOVA with repeated 
measures was used followed by Bonferroni post-hoc tests when significant main effects were 
found. A P value < 0.05 was considered statistically significant for all statistical comparisons. All 
statistical comparisons were performed with Prism 5 software (GraphPad, La Jolla, CA).   
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RESULTS 
Amygdala mGluR5 activation induces bladder hypersensitivity  
In order to study pain-like behavior originating from the bladder as directly as possible, 
we chose to study the response to urinary bladder distention (Figure 4.1A).  The behavioral 
response to bladder distension is quantified using the visceromotor response (VMR), which is an 
electromyographic (EMG) recording of the abdominal muscle contraction in response to bladder 
distension (Ness and Gebhart, 1988, 1991; Ness and Elhefni, 2004).  Previous studies have 
demonstrated a critical role for mGluR5 activation in the right amygdala in the development of 
somatic pain sensitization (Ji and Neugebauer, 2009; Kolber et al., 2010) but it is not known 
whether mGlu5 also regulates bladder nociception. To address this question, the selective 
mGluR1/5 agonist, DHPG, was infused to the right amygdala via an indwelling cannula (Figure 
4.1B) and the effects of this infusion on the VMR to bladder distension was measured.  Bladder 
distention (20-80 mmHg distension in 10 mmHg steps) reliably produces an evoked VMR that 
increases with increasing distension pressure (Figure 4.1A) (Figure 4.1C, 2-way ANOVA main 
effect of pressure F6,42=8.2 P<0.0001; Figure 4.1D F6,42=26.3 P=0.0019).  When a control vehicle 
is infused, and the bladder distension protocol is repeated, no changes in the evoked response 
are observed (Figure 4.1D).  In contrast, infusion of DHPG (0.1nmol) significantly increased the 
evoked responses to bladder distension compared to pre-treatment baseline values (Figure 4.1C, 
2-way ANOVA significant main effect of treatment, F1,42=26.3 P<0.0001; before DHPG versus 
after DHPG Bonferroni post-hoc test at 50 mmHg t=2.9 P<0.05). Thus, activation of mGluR1/5 in 
the right CeA results in significant physiological sensitization to bladder distension.    
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Figure 4.1.  Intra-Amygdala DHPG results in hyperalgesia to bladder distention.   A, 
Illustration of in vivo urinary bladder distention visceromotor response (VMR) setup.   
Compressed air guided into the bladder with a catheter is used to distend the bladder.  Distention 
induces a visceromotor response that is recorded as an electromyogram (EMG) from the 
abdominal muscles.  Representative EMG traces show that the VMR response increases with 
increasing bladder distention pressure.  B, Mice are cannulated in the right central nucleus of the 
amygdala (CeA) and drug is delivered via the cannula.   C, Infusion of an mGluR1/5 agonist, 
DHPG (0.1 nmol), into the right CeA (n=7) induces a hyperalgesic response to graded bladder 
distention compared to baseline (pre-treatment) values.  EMG inset shows representative EMG 
trace to 50 mmHg distention at baseline and following DHPG treatment (step represents 20 sec 
distention stimulus).  Brain atlas insets show cannula targeting with black stars indicative of 
cannula tip.  D, Treatment with intra-amygdala vehicle (aCSF) (n=7) had no effect on the evoked 
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response to graded bladder distention.  Brain atlas insets show cannula targeting with white stars 
indicative of cannula tip.   (***P<0.001 2-way ANOVA main effect of treatment; *P<0.05 
Bonferroni post test compared to baseline value) 
 
Intra-amygdala mGluR5 antagonism decreases evoked responses to bladder distention 
Prior evidence suggested that mGluR5 in the amygdala is involved in the modulation of 
somatic pain only after injury and that mGluR5 signaling does not affect acute responses to 
noxious stimulation (Kolber et al., 2010; Li et al., 2011).  Whether mGluR5 modulates acute 
responses to bladder stimulation is not known, however.  To address the role of amygdala 
mGluR5 in the modulation of bladder pain, the mGluR5 antagonist MPEP (or vehicle) was 
delivered locally to the right amygdala between two rounds of bladder distensions (from 20 to 80 
mmHg in 10 mmHg increments) and the effects on the evoked VMR were determined.  We found 
that MPEP infusion to the CeA induced a significant decrease in bladder distention-evoked 
responses (2-way ANOVA significant main effects of pressure F6,35=5.9 P=0.0003 and treatment 
F1,35=22.45 P<0.0001) that was particularly noticeable at the higher noxious pressures (Figure 
4.2A, before MPEP versus after MPEP Bonferonni post-hoc test at 70 mmHg t=4.5 P<0.001 and 
at 80 mmHg t=6.1 P<0.001) compared to baseline VMRs.   These results were corroborated in a 
second experiment where we measured the effect of pretreatment with MPEP on the VMR to a 
single round of noxious distension of the bladder with no baseline distention.  We found that mice 
that had received infusion of MPEP into the right CeA had significantly decreased VMR to high 
noxious (80 mmHg) bladder distention when compared to responses in vehicle-infused mice 
(Figure 4.2C, Student’s t-test t11=2.3 P=0.04). These findings provide further support for the 
notion that mGluR5 activation in the amygdala is required for acute regulation of bladder 
nociception.  
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Figure 4.2. Intra-amygdala MPEP 
is analgesic during bladder 
distention.  A, Infusion of a 
mGluR5 antagonist, MPEP 
(0.01nmol), into the right CeA (n=6) 
induced an analgesic response to 
graded bladder distention in the 
noxious range compared to 
baseline (pre-treatment) values.  
Inset shows representative EMG 
traces to 70 and 80 mmHg 
distention at baseline and following 
MPEP treatment (step represents 
20 sec distention stimulus). Brain 
atlas insets show cannula targeting 
with black stars indicative of 
cannula tip.   B, Treatment with 
intra-amygdala injection of vehicle 
(aCSF) (n=6) induced a significant 
increase in evoked response 
during bladder distention.   
However, this change was in the 
opposite direction of treatment with 
MPEP and likely represents a small 
non-specific effect possibly due to 
repeated bladder distention.  Brain 
atlas insets show cannula targeting 
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with white stars indicative of cannula tip.    C, In a separate cohort, pre-treatment with MPEP 
(n=7) before a single round of higher noxious pressure bladder distention (i.e. no baseline 
distention) induced a significant decrease in the evoked response compared to vehicle-treated 
mice (n=6).  Brain atlas insets show cannula targeting with solid black stars indicative of cannula 
tip of MPEP-treated mice and white stars indicative of cannula tip of vehicle-treated mice.    
(***P<0.001 2-way ANOVA main effect of treatment; +++P<0.001 Bonferroni post test compared 
to indicated baseline value; *P<0.05 Student’s t-test compared to vehicle-treated group)  
 
Surprisingly, when vehicle was infused between two rounds of graded bladder distension, 
the evoked responses were significantly increased relative to pre-infusion baseline 
measurements (Figure 4.2B, 2-way ANOVA significant main effects of pressure F6,35=5.0 
P=0.0009 and treatment F1,35=15.4 P=0.0004).   These results might suggest that repeated 
distension to noxious pressures can induce mild sensitization of the bladder.   To address this 
issue, we examined the VMR in control mice that received only a single round (4-5 distentions) of 
80mmHg distention (with no baseline UBD).  Comparing the VMR after the first distention at 
80mmHg in these mice to the last distention, we found no significant sensitization of the VMR to 
repeated distentions (1st distention = 0.54 + 0.10 evoked response; last distention = 0.30 + 0.05 
evoked response; paired t-test t5=1.9 P=0.11).  These data suggest that repeated bladder 
distention does not sensitize the bladder.  
Disruption of mGluR5 in the right amygdala reduces responses to bladder distension     
The results described above demonstrate that pharmacological activation of mGluR5 in 
the right CeA enhances the evoked response to bladder distension whereas inhibition of mGluR5 
in the CeA inhibits these responses.  These data are consistent with the hypothesis that mGluR5 
in the right CeA plays a central role in the endogenous modulation of visceral bladder pain.  
However, pharmacological manipulations in vivo can always have the potential for off-target 
effects.  To compliment our pharmacological studies, we took a genetic approach to test the 
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hypothesis that endogenous mGluR5 activation is required for bladder pain.  A conditional 
knockout approach was used to specifically disrupt mGluR5 expression in the right CeA using 
recombinant lentivirus-mediated expression of Cre recombinase (LV-Cre) in floxed mGluR5 mice. 
Floxed mGluR5 mice injected with LV-Cre (mGluR5CeAKO) exhibited a significant decrease in 
mGluR5 protein levels when compared with mGluR5 expression in the right amygdala of LV-Cre 
injected WT (control) mice, thus confirming deletion of mGluR5 (Figure 4.3A, Student’s t-test 
t9=3.8 P=0.0045).  




disruption of mGluR5 in the 
central amygdala is 
analgesic.  A, Representative 
Western blot for mGluR5 (top) 
and b-tubulin (bottom) in 
mGluR5CeAKO and WT LV-Cre-
injected (control) mice. Graph 
of mGluR5/b-tubulin shows 
reduced mGluR5 expression 
in the right amygdala of 
mGluR5CeAKO mice (n=8) 
compared to the right 
amygdala of control mice 
(n=8).   B, Disruption of 
mGluR5 in the right amygdala 
(n=8) induced a significant 
decrease in evoked response 
during bladder distention 
compared to control mice 
(n=9).   Brain atlas insets 
show cannula targeting with 
black squares indicative of cannula tips of control mice and gray triangles indicative of cannula 
tips of mGluR5CeAKO mice.      (***P<0.001 2-Way ANOVA main effect of genotype; **P<0.01 
Student’s t-test) 
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To measure the impact of CeA mGluR5 disruption on bladder pain-related behavior, we 
compared the responses of mGluR5CeAKO to control mice during graded bladder distention 
(distention from 20-80 mmHg in 10 mmHg steps).  We found a significant decrease in the evoked 
response to bladder distension in the mGluR5CeAKO mice compared to control mice (Figure 4.3B, 
2-way ANOVA significant main effects of pressure F6,105=7.8 P<0.0001 and genotype F1,105=14.4 
P=0.0003).  Overall, these data suggest that mGluR5 activity in the CeA modulates ongoing 
sensitivity to visceral stimulation. 
Amygdala control of bladder hyperalgesia is associated with ERK activation in the spinal 
cord 
Next, we sought to evaluate the mechanisms by which activation of the CeA might 
modulate evoked responses to bladder distention. We hypothesized that mGluR5 activation in the 
CeA could modulate bladder nociception by regulating ERK1/2 activity in the CeA or spinal cord 
(through modulation of descending pathways).  We first tested whether bladder distention in naive 
mice would induce ERK1/2 phosphorylation.  We compared the protein collected from the 
lumbosacral spinal cord and the CeA in mice distended 5 times at 80 mmHg to protein from 
undistended sham mice.  We found that bladder distension induced a significant increase in 
phosphorylated ERK1 and ERK2 in the spinal cord (Figures 4.4A-B, Student’s t-test pERK1 
t12=2.6 P=0.022; pERK2 t12=3.3 P=0.0068).  In contrast, we found no significant change in 
activation of ERK1 or ERK2 in the CeA following distention compared to sham mice (Figures 
4.4C-D).  
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Figure 4.4.  Bladder distention induces spinal cord ERK phosphorylation.  A, 
Representative Western blot showing phosphorylated ERK1 & ERK2 bands (top) and total ERK1 
& ERK2 (bottom) from spinal cord tissue of undistended control (sham) mice (n=7) or 80 mmHg 
bladder distended mice (n=7).   B, Quantification of Western blots showing increased ERK1 and 
ERK2 phosphorylation in distended mice compared to sham mice.  C, Representative Western 
blot showing phosphorylated ERK1 & ERK2 bands (top) and total ERK1 & ERK2 (bottom) from 
left and right amygdala of sham mice or 80 mmHg bladder distended mice.   D, Quantification of 
Western blots showing no significant change ERK1 and ERK2 phosphorylation from right 
amygdala tissue samples of distended mice compared to sham mice. (*P<0.05, **P<0.01 
unpaired Student’s t-test compared to sham group) 
 
Since bladder distension induced an increase in activated ERK1/2 in the spinal cord and 
we found a decrease in the evoked response to bladder distention in mGluR5CeAKO mice, we 
reasoned that mGluR5CeAKO mice might show a decrease in spinal ERK1/2 activation following 
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bladder distention.  Indeed, we found that disruption of mGluR5 in the right CeA caused a 
significant decrease in the phosphorylation of ERK1 and ERK2 in the spinal cord after bladder 
distention compared to distended control mice (Figures 4.5A-B, Student’s t-test pERK1 t14=2.3 
P=0.038; pERK2 t14=2.3 P=0.035).  These data suggest the presence of tonic modulation of 
spinal circuitry driven by mGluR5 activation in the CeA.   In contrast, when we compared the 
phosphorylation of ERK1 and ERK2 by Western analysis in the spinal cord after CeA treatment 
with MPEP or vehicle followed by a single round of noxious distention, we failed to find any 
significant differences between groups (data not shown).   
 
Figure 4.5.  Genetic disruption of mGluR5 in the right amygdala reduces bladder 
distention-induced ERK phosphorylation.   A, Representative Western blot showing 
phosphorylated ERK1 & ERK2 bands (top) and total ERK1 & ERK2 (bottom) from spinal cord 
tissue from LV-Cre injected control mice (n=9) or mGluR5CeAKO mice (n=7) following graded 
bladder distention.  B, Quantification of Western blots showing decreased ERK1 and ERK2 
phosphorylation in mGluR5CeAKO mice compared to control mice.  (*P<0.05 unpaired Student’s t-
test compared to control group) 
 
Optogenetic activation of the central amygdala is sufficient to induce pain hypersensitivity 
with no changes in ERK1/2 phosphorylation 
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The mechanisms through which mGluR5 in the CeA might modulate responses to 
bladder distention are unknown. For example, mGluR5 activation in the CeA could suppress a 
tonically active descending inhibitory pathway to the spinal cord, or conversely could drive 
increased descending excitatory circuitry.  To address the hypothesis that an overall increase in 
the activity of CeA neurons may be sufficient to induce bladder hyperalgesia, we utilized an 
optogenetic approach to drive excitation of CeA neurons and asked whether this increased CeA 
activity could modulate the VMR elicited by innocuous and noxious bladder distension.   
To accomplish this goal, channelrhodopsin-2 or control protein expression was driven in 
the CeA by targeted injection in the right CeA (Figure 4.6A) of HSV vectors expressing YFP only 
(HSV-YFP control; Figure 4.6B) or channelrhodopsin-2 fused to YFP (HSV-ChR2-YFP; Figure 
4.6C). Four days after viral injection, mice were stimulated with low (30 mmHg) or with higher 
noxious (60 mmHg) bladder distention at baseline, during, and after laser stimulation (5ms, 20Hz 
pulse with 18ms spike width).  The optical stimulation protocol chosen for these experiments was 
modeled to mimic the CeA neuronal firing pattern that occurs after injury in rodents (Ji and 
Neugebauer, 2009).  In HSV-YFP control mice, optical stimulation did not alter evoked responses 
to bladder distention at 30 mmHg (Figures 4.6D,F) or 60 mmHg (Figures 4.6G,I).  In contrast, 30 
minutes of optical stimulation of HSV-ChR2-YFP treated mice caused a significant increase in 
bladder distention-evoked responses compared to baseline measurements (Figures 4.6E-F, H-I, 
Bonferroni post-hoc test at 30 mmHg t=2.5 P<0.05 and at 60 mmHg t=4.3 P<0.001) and 
compared to HSV-YFP control mice (Figure 4.6I, Bonferonni post-hoc test at 60 mmHg t=3.0 
P<0.05).  Interestingly, CeA stimulation induced a lasting hypersensitivity to bladder distention in 
HSV-ChR2-YFP treated mice.  That is, 15 min after the laser stimulation was terminated, HSV-
ChR2-YFP treated mice still showed increased responses to bladder distention (Figures 4.6E-F, 
Bonferonni post-hoc test at 30 mmHg compared to baseline t=2.8 P<0.05; Figures 4.6H-I, at 60 
mmHg compared to baseline t=4.6 P<0.001 and at 60 mmHg compared to HSV-YFP control mice 
t=3.1 P<0.05).   
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Figure 4.6. Optogenetic stimulation of right central amygdala induces bladder 
hyperalgesia.   A, Mice are cannulated in the right central nucleus of the amygdala (CeA) and 
HSV vectors are delivered via the cannula.  B-C, YFP fluorescence (via immunohistochemistry) is 
seen in the CeA of both (B) HSV-YFP (control vector) and (C) HSV-ChR2-YFP (optogenetic 
vector) injected mice (scale bars = 0.2mm).  Differences in staining pattern for HSV-YFP versus 
HSV-ChR2-YFP-treated mice are likely due to the fact that there is probably higher expression of 
cytoplasmic YFP (i.e. HSV-YFP) compared to the ChR2-YFP fusion protein, which is membrane 
bound.  Brain atlas insets show cannula targeting with black squares indicative of cannula tips of 
HSV-YFP mice and white hexagons indicative of cannula tips of HSV-ChR2-YFP mice.      
Representative images of raw EMG traces from HSV-YFP or HSV-ChR2-YFP injected mice 
during (D-E) 30 mmHg and (G-H) 60 mmHg bladder distention.  Optic stimulation of HSV-ChR2-
YFP treated mice (n=7) increases the evoked response to both 30 and 60mmHg bladder 
distention compared to (E,H) baseline (pre-stimulation) responses and increases the evoked 
response to 60 mmHg bladder distention compared to (I) HSV-YFP injected mice (n=5).  Laser 
light alone does not increase the evoked response to bladder distention in HSV-YFP mice (D, F, 
G, I).   Black steps in traces show 20sec bladder distention stimuli.   (*P<0.05; ***P<0.001 
Bonferroni post test compared to baseline for HSV-ChR2-YFP mice; #P<0.05 Bonferroni post test 
compared to HSV-YFP control mice at indicated time points) 
 
To test one possible downstream effect of optogenetic activation of the amygdala, we 
evaluated whether optogenetically driven activation of the amygdala (5ms, 20Hz pulse with 18ms 
spike width) in the absence of bladder distention would induce spinal cord ERK1/2 
phosphorylation.  Mice received local infusions in the CeA of HSV-ChR2-YFP or HSV-YFP as 
described above.   Four days after viral infusion, mice were anesthetized and stimulated with the 
laser on for 30 min and were killed after the laser had been off for 15 min. Comparing spinal cord 
protein samples analyzed by Western or spinal cord sections analyzed for pERK1/2 
immunofluorescence, we found that optogenetic stimulation of the CeA failed to induce an 
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increase in ERK1/2 phosphorylation compared to HSV-YFP control mice (Western: Student’s t-
test pERK1 HSV-YFP n=12 1.0 + 0.08 vs HSV-ChR2-YFP n=10 1.0 + 0.09 t=0.1 P=0.93; pERK2 
HSV-YFP 1.0 + 0.07 vs HSV-ChR2-YFP 1.1 + 0.07 t=0.7 P=0.51)(IHC: Student’s t-test deep 
dorsal commissure HSV-YFP n=3 40.0 + 10.6 vs HSV-ChR2-YFP n=3 38.9 + 5.5 pERK1/2 
positive cells t=0.10 P=0.92; spinal parasympathetic nuclei HSV-YFP 23.0 + 8.9 vs HSV-ChR2-
YFP 29.5 + 2.3 pERK1/2 positive cells t=0.82 P=0.45; lateral dorsal horn HSV-YFP 12.6 + 2.4 vs 
HSV-ChR2-YFP 13.2 + 4.1 pERK1/2 positive cells t=0.11 P=0.91; medial dorsal horn HSV-YFP 
15.3 + 6.9 vs HSV-ChR2-YFP 16.6 + 3.8 pERK1/2 positive cells t=0.18 P=0.86; total dorsal horn 
HSV-YFP 90.8 + 25.6 vs HSV-ChR2-YFP 98.1 + 12.7 pERK1/2 positive cells t=0.28 P=0.79). 
Similar to our results with optogenetic activation, treatment of the CeA with DHPG in the absence 
of bladder distention did not alter ERK1/2 phosphorylation in the spinal cord compared to vehicle-
treated mice (data not shown). 
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DISCUSSION 
  Our results demonstrate that activation of group I mGluRs in the right amygdala was 
sufficient to induce an increased pain response to bladder distention.  Furthermore, 
pharmacological inhibition and genetic deletion of mGluR5 in the right amygdala resulted in a 
reduced response to bladder distention. Optogenetic activation of the right amygdala was 
sufficient to increase the pain response to bladder distention. Together, these results suggest that 
mGluR5 in the right CeA modulates bladder pain responses via increased excitation of CeA 
neurons.  Our results are consistent with previous work demonstrating that noxious bladder 
distention in the absence of injury results in ERK1/2 activation in the lumbosacral spinal cord (Lai 
et al., 2011).  Furthermore, we found that the level of activated ERK1/2 is dependent on the 
presence of mGluR5 in the right CeA.  Our results suggest that distension-evoked ERK1/2 
activation in the lumbosacral spinal cord is modulated in part by mGluR5 activity in the right 
amygdala.      
Here, we show for the first time that mGluR5 in the right CeA is necessary for the visceral 
bladder pain response to noxious stimuli.  Our results are consistent with previous work indicating 
that activation of Group I mGluRs in the right amygdala leads to increased somatic pain (Kolber 
et al., 2010). Specifically, activation of mGluR5 in the right amygdala results in bilateral 
mechanical hypersensitivity (Kolber et al., 2010). Our results extend this phenomenon to visceral 
bladder pain and suggest that pharmacological activation of group I mGluRs (mGluR1 and 5) in 
the right CeA is sufficient to increase the nociceptive responses to bladder distention in naïve 
(non-injured) mice.  
Given that previous studies have shown the mGluR1/5 agonist DHPG potentiates the 
excitatory response of the CeA during visceral colorectal distention (Ji and Neugebauer, 2010), 
we hypothesized that activation of Group I mGluRs in the amygdala could lead to increased 
excitability as has been reported previously (Li and Neugebauer, 2004), thus resulting in the 
observed increased response to bladder distention. We demonstrate that optogenetic stimulation 
of CeA neurons in the right amygdala is sufficient to increase the VMR to urinary bladder 
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distention. Furthermore, this increased VMR is maintained 15 minutes after the optogenetic 
activation is turned off.   Injury in a colitis model increases the excitability of evoked responses in 
the CeA (Han and Neugebauer, 2004) and arthritis-induced somatic injury increases the 
background and evoked responses of CeA neurons (Li and Neugebauer, 2004).  The sustained 
behavioral response we observe after optical excitation suggests that 30 min activation of the 
CeA may, in effect, model the changes seen after either visceral or somatic injury. Future studies 
are required to test this hypothesis.   
Our previous studies have shown that inhibition of mGluR5 in the right amygdala reduces 
persistent injury-induced hypersensitivity of the paw, but that inhibition of mGluR5 does not alter 
acute somatic sensitivity or spontaneous somatic nociceptive responses (Kolber et al., 2010).  
Here, we find that pharmacological inhibition of mGluR5 following a round of bladder distension is 
analgesic when compared to the baseline bladder distention.  These results could represent 
either a novel role of mGluR5 in modulating acute visceral sensation or provide additional 
evidence that mGluR5 modulates sensation after mild injury caused by repeated bladder 
distensions. We believe that the significant increase in the evoked response in the vehicle-treated 
mice (Figure 4.2B) is likely a statistical aberration as no such effect was seen in a similar 
experiment (Figure 4.1D), and we found that the first VMR is not significantly different from the 
last VMR during a round of noxious bladder distention with no baseline testing.  Nonetheless, to 
unequivocally determine whether mGluR5 in the CeA modulates baseline (uninjured) responses 
to bladder distension, we inhibited mGluR5 before noxious stimulation with no baseline distention 
trials.  Providing evidence for the hypothesis that mGluR5 modulates acute bladder nociception, 
mice pretreated with MPEP have a smaller VMR in response to a single round of 80 mmHg 
distension when compared to vehicle-treated mice. This hypothesis is further supported by the 
reduced VMR observed in mice with conditional disruption of mGluR5 in the right amygdala, 
because these animals receive only a single series of distensions.  Interestingly, these data are 
contrary to previous reports showing that inhibition of mGluR5 in the right amygdala has no effect 
on vocalizations induced by visceral colorectal distention (Li et al., 2011). One possible 
explanation for this apparent discrepancy is that there are inherent differences in the responses 
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measured (e.g. vocalizations (Li et al., 2011) versus reflexive abdominal contractions).  Our novel 
results demonstrate that ongoing mGluR5 activity in the right CeA modulates the visceromotor 
response to noxious bladder distention in naive (uninjured) mice.   
The mechanism of the modulation of distension-evoked bladder pain by CeA-localized 
mGluR5 seems to be related in part to a modulation of ERK1/2 in the spinal cord.  Our previous 
experiments have demonstrated that ERK1/2 in both the spinal cord and amygdala is involved in 
the modulation of acute spontaneous somatic pain and behavioral changes after injury 
(Carrasquillo and Gereau, 2007; Hu et al., 2007; Carrasquillo and Gereau, 2008).  Furthermore, 
we know from previous work that ERK1/2 is activated in the dorsal horn neurons of the 
lumbosacral spinal cord (lamina I, II, V, X) following bladder distention in mice with and without 
bladder inflammation (Lai et al., 2011).  Our results suggest that noxious bladder distention in 
lightly anesthetized mice immediately activates ERK1/2 in the lumbosacral spinal cord, but not in 
the amygdala.  Furthermore, genetic deletion of mGluR5 in the right CeA reduced activation of 
ERK1/2 in the lumbosacral spinal cord following bladder distention.  In contrast, pharmacologic 
inhibition of mGluR5 with MPEP did not change the activation of ERK1/2 following noxious 
distention.  This difference may be related to the long-term disruption that exists in the knockout 
mice compared to the acute inhibition in the MPEP experiment, or a difference in the extent of 
mGluR5 inhibition achieved by the two approaches.  Nonetheless, these data suggest the 
presence of a functional connection between the amygdala and the spinal cord nociceptive 
neurons.     
To further test this connection, we activated the amygdala (via optogenetic or 
pharmacologic techniques) in the absence of bladder distention and measured ERK1/2 
phosphorylation in the spinal cord.  Finding no effect of amygdala activation on pERK1/2 in the 
spinal cord, these results suggest either that ERK1/2 modulation occurs only in the context of 
nociceptive input (e.g. bladder distention) and/or that there are other changes that occur in the 
spinal cord during amygdala activation.   Nociceptive neurons in the CeA project to the PAG and 
then to the rostral ventromedial medulla (RVM) (Neugebauer et al., 2004).  Descending inputs 
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from the RVM exert facilitatory and inhibitory influence on nociceptive transmission in the spinal 
cord dorsal horn (Millan, 2002; Porreca et al., 2002; Ren and Dubner, 2002). Modulation of 
visceral nociception between the amygdala and the spinal cord could occur at the sensory 
fiber/spinal cord synapse (in the spinal cord dorsal horn), on modulatory interneurons, or 
potentially on motor neurons that mediate abdominal contractions during bladder distention. 
Future studies will be necessary to determine the precise location and mechanism of this 
interaction.    
 Overall, our results suggest that increased CeA output, driven by mGluR5 activation, in 
combination with bladder distention leads to modulation of ERK activation in the spinal dorsal 
horn. These results highlight the important role that limbic brain structures play in the regulation of 
peripheral responses to noxious stimuli.  Furthermore, our results showing that mGluR5 inhibition 
modulates acute visceral nociception provide evidence for a novel role of the amygdala in the 
modulation of on-going nociception in the absence of injury or external stress.             
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Overview on the Anatomical and Molecular Examination of Bladder Pain 
Although the etiology of IC/PBS is unknown, there are many hypotheses on how IC/PBS 
develops (See chapter 1, Figure 1.1) (Keay, 2008; Hanno et al., 2010; Birder, 2011).  
Understanding the molecular modulation of bladder pain is vital to the development of therapeutic 
targets. The overall goal of this thesis is to increase understanding of how bladder pain is 
modulated in two anatomical areas; the bladder and in the amygdala. In chapter 2 of this thesis, 
we test the hypothesis that distinct bladder injuries differentially affect bladder pain.  Using three 
distinct models of bladder injury, our results demonstrate that not all bladder injuries result in 
increased sensitivity to bladder distention.  Previous work has suggested that mGluR5 in the CNS 
may modulate non-inflammatory bladder pain (Hu et al.).  In chapter 3, we test the hypothesis 
that mGluR5 is necessary for the full expression of inflammatory and non-inflammatory bladder 
pain.  We found that systemic deletion or inhibition of mGluR5 significantly reduced the evoked 
response to bladder distention.  Furthermore, systemic inhibition of mGluR5 was analgesic to 
distention-induced inflammatory and non-inflammatory bladder pain.  However, mGluR5 is 
expressed throughout the pain neuroaxis.  In chapter 4 of this thesis, we test the hypothesis that 
amygdala mGluR5 is necessary for the modulation of bladder pain.  These data suggest that 
mGluR5 in the central nucleus of the amygdala is necessary for the full expression of distention-
induced bladder pain.  Furthermore, these data suggest that mGluR5 in the amygdala has a role 
in descending modulation of nociception in the spinal cord.    
Differential Injury to the Bladder Results in Distinct Evoked-Responses to Bladder Distention 
Bladder pain has been extensively modeled through the use of noxious inflammation-inducing 
chemical agents such as hydrochloric acid, turpentine, mustard oil, LPS, and CYP (Westropp and 
Buffington, 2002).  However, the nature of the injury to the urothelium that results in increased 
pain after bladder distention was undetermined.  To accomplish this goal, we examine how three 
different bladder injury models affect the nocifensive response to bladder distention.  Using these 
distinct injury models we discovered that not all bladder injuries lead to increased pain-like 
responses to bladder distention.  Furthermore, the results from chapter 2 highlight that careful 
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correlation of urine cytology and bladder histology with VMR measurements are key in 
determining how differential injuries affect the pain response to bladder distention.   
Previous studies have shown that UPEC infection causes inflammation and activation of the 
basal stem cells and barrier disruption (Mysorekar et al., 2009). As described in chapter 2, our 
results show that infection with UPEC strain UTI89 also causes increased evoked-responses to 
bladder distention. Taken together, these data suggest that the combination of inflammation, 
activation of the basal cell layer and loss of barrier cells (SFCs) results in an increased sensitivity 
to bladder distention.   
The increased sensitivity to bladder distension in UPEC-infected mice may be related to the 
binding of the bacterial product LPS, as demonstrated in a recent publication (Rudick et al., 
2010). Therefore, we examined how chronic treatment with the bacterial endotoxin LPS 
(produced by E. coli O55:B5) modulates the response to bladder distention.   As reported in 
chapter 2, chronic (4 day) treatment with the bacterial endotoxin LPS had no effect on bladder 
inflammation or the evoked response to bladder distention when compared to similarly treated 
controls. It was surprising to discover that chronic treatment with a highly immunogenic 
compound did not result in increased sensitivity to bladder distention or chronic inflammatory 
changes. The urine cytology from these mice suggests that the peak window of inflammation 
occurs on days 1 and 2 after LPS treatment, indicating that we had not measured the response to 
bladder distension during peak inflammation.  Although this protocol has previously shown 
chronic inflammatory changes (Saban et al., 2002) using a much larger volume (200ul versus 
50ul of 100mg/ml LPS), intravesicular volumes greater than 50ul increase the vesicoureteral 
reflux (Schaeffer et al., 1987; Hung et al., 2009) and cause pain that does not originate from the 
bladder.  Increased pain and inflammatory changes from LPS in the ureters would complicate our 
hypothesis examining how injury to the bladder results in distention-induced bladder pain.  For 
this reason, we used a more appropriate intravesicular volume of 50ul to induce chronic bladder 
inflammation.  However, in our hands, 4 days of LPS treatment did not induce chronic 
inflammatory changes (Saban et al., 2002).  This failure could be due to a reduced volume 
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decreasing the total amount of LPS instilled into the bladder.  To test the hypothesis that chronic 
LPS-induced inflammation is dose-dependent, we could repeat the urine cytology and histology 
studies with an increased concentration of LPS (4x the concentration used previously 400mg/ml) 
delivered in the 50ul volume.  If this replicates the chronic inflammatory changes seen by Saban 
et al (Saban et al., 2002), it would support the hypothesis that the chronic inflammatory changes 
are dependent on the total LPS dosage.  If we did not observe inflammatory changes at this 
higher dose of LPS, then the chronic inflammatory changes previously reported might be the 
result of LPS entering the ureters.  Alternatively, the failure to develop inflammation after chronic 
LPS treatment could be due to the type of LPS used. Recent work has demonstrated that 
different strains of E. coli result in distinct levels of bladder pain, largely due to differences in LPS 
composition (Rudick et al., 2010).  Even though we used the same type of LPS used in the 
previous study (Saban et al., 2002), it is possible that there are batch-dependent differences in 
the LPS we obtained and the LPS used previously in 2002.  To test the hypothesis that the lack of 
observed chronic inflammation in LPS (strain O55:B5) treated mice was an LPS-dependent 
effect, we could use LPS purified from UPEC (UTI89).  Although infection with UPEC strain UTI89 
is capable of inducing chronic bladder infection (Cusumano et al., 2011; Schwartz et al., 2011), it 
is not certain that chronic treatment with LPS from UPEC UTI89 would necessarily result in 
chronic inflammation.  If we were unsuccessful at inducing chronic inflammation, with LPS-
derived from UPEC, we could still examine the differences in bladder pain responses to acute 
LPS treatment and acute UPEC infection. Acute application of UPEC-derived LPS would 
elucidate if acute UPEC-induced inflammation is due to LPS or another (LPS-independent) 
mechanism. 
In surprising contrast with UPEC treatment, treatment with protamine sulfate (PS) was analgesic 
when compared to similarly treated PBS controls.  PS treatment, at the dose used, is known to 
induce exfoliation of the superficial cell layer of the urothelium without inflammation or activation 
of the stem cell niche (Mysorekar et al., 2009).  Beyond the important barrier function, there is 
increasing evidence to suggest that the urothelium plays a key role in the detection and 
transmission of physiological and nociceptive stimuli (Birder, 2011).  It is possible that the 
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exfoliated superficial cells have a key role in the sensory function of the urothelium.  Therefore, 
PS-induced exfoliation of SFCs may result in the bladder temporarily losing the ability to ‘sense’ 
distention-induced pain.  This may be regulated by decreases in molecules such as IL-1β which 
known to directly activate nociceptors.  We found that in mice treated with PS, the level of IL-1β in 
the bladder tissue was significantly reduced following PS-treatment.  It has been demonstrated 
that IL-1β is produced by the bladder urothelium (Wood et al., 2011) and smooth muscle cells 
(Bouchelouche et al., 2006) in response to inflammatory injury.  However, the specific IL-1β 
producing cells in the urothelium are not known.  We could determine if SFCs are responsible to 
the production of IL-1β by quantifying the level of IL-1β in the SFCs that are exfoliated in the urine 
following PS treatment.  If the exfoliated SFCs in PS express high amounts of IL-1β it could 
explain the dramatic decrease in cytokine expression.  However, we would need to examine 
where in the urothelium IL-1β was being produced in UPEC treated mice since both UPEC and 
PS treated mice have SFC exfoliation.   
Interestingly, in addition to a decreased sensitivity to bladder distention, PS treatment was 
protective against distention-induced damage to the bladder. The mechanism by which exfoliation 
of the superficial cells could protect the bladder against stretch-induced injury is unknown.  While 
the bladder is uniquely tolerant of stretch, the pressures we used to elicit pain were supra-
physiologic.  One explanation for this is that the tight junctions formed by the superficial cell layer 
prevent stretching at very high pressures.  Therefore, the chemically-induced exfoliation of the 
SFCs would allow the bladder to stretch past the point at which the tight-junctions would cause 
damage as a result of cell shearing.  We could test this hypothesis using scanning electron 
microscopy to could compare the structure of a highly stretched urothelium with and without the 
presence of SFCs.  If equal stretch of the urothelium induces the SFCs to shear at their tight 
junctions but causes no damage in samples that experienced shearing, it would support this 
hypothesis.    
An additional observation reported in chapter 2 is that PS treated mice had frank hematuria 
following noxious distention despite less pain.  In all mice with distention-induced hematuria, 
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pyuria (urine inflammation) was inversely correlated with the presence of hematuria (see 
supplementary figure 2.1).  Scanning-electron microscopy of the stretched bladder urothelium 
might indicate if the hematuria in PS-treated mice is the result of shearing of the capillaries in the 
bladder wall.    
The results presented in chapter 2 suggest that activation of the stem cell niche or inflammation 
has a role in the development of increased pain to bladder distention.  UPEC treatment results in 
both stem cell activation and increased inflammation while PS treatment does not (Mysorekar et 
al., 2009).  Furthermore, in our hands, LPS treatment did not cause increased inflammation or 
stem cell activation (data not shown).  To test the hypothesis that increased bladder pain is the 
result activation of the stem cell niche and not inflammation; we could use a double dose 
treatment of PS (ddPS).  This technique was recently established in the Mysorekar lab, and they 
demonstrate that ddPS induces both barrier damage and activation of the basal cell layer (stem 
cells) without inflammation (unpublished observation by KMS and IUM).  If mice treated with 
ddPS had an increased VMR to bladder distention when compared to PBS-treated controls, then 
this would suggest that stem cell activation are, and inflammation is not, important for the 
development of distention-induced bladder pain.  If ddPS treated mice had a reduced response to 
bladder distention, it might suggest that barrier disruption in the absence of inflammation is 
analgesic in this mouse model of bladder pain.        
Overall, the results from chapter 2 demonstrate that UPEC-induced injury results in a significantly 
enhanced nociceptive response to bladder distention whereas chronic LPS treatment did not. 
Furthermore, UPEC infection but not chronic LPS treatment resulted in sustained bladder tissue 
inflammation and inflammatory efflux into the urines. Most intriguingly however, chemical injury 
with PS results in a reduced pain response to bladder distention and protection from distention-
induced damage to the bladder architecture. This is the first report, to our knowledge, of an injury 
resulting in an analgesic response to bladder distention.  Through the use of three injury models 
and analysis of the impact of these on nociceptive responses, we have differentiated unique 
molecular signals that may modulate bladder pain from those that modulate injury, including IL-6, 
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IL-1β, IL-4 and SOCS3.  Taken together, our data suggest that 1) differential injury to the 
urothelium results in distinct nociceptive responses, with not all injuries leading to increased pain 
and 2) that detailed histological and urinary characterization in combination with analysis of pain 
responses is an innovative method for identification of novel mediators of visceral pain. 
 
mGluR5 is Necessary for The Full Expression of Bladder Pain 
A large body of evidence implicates mGluR5 in the development of hyperalgesia following a 
somatic inflammatory injury (Varney and Gereau, 2002; Cruz and Cruz, 2007; Montana et al., 
2009; Kolber et al., 2010).  Additionally, there is limited evidence suggesting a role for mGluR5 in 
visceral pain (Bianchi et al., 2003; Blackshaw et al., 2011), and in the modulation of non-
inflammatory bladder pain (Hu et al., 2009).  However, the role of mGluR5 in inflammatory 
bladder pain was undetermined.  In chapter 3 of this thesis, we hypothesized that mGluR5 is an 
important modulator of inflammatory and non-inflammatory bladder pain.  To test this hypothesis, 
we compared the VMR of mGluR5 KO mice to their WT littermates.  mGluR5 KO mice had a 
significantly smaller evoked response to bladder distention when compared to WT littermate 
controls. Furthermore, systemic treatment with a specific antagonist of mGluR5 also the reduced 
evoked-response to bladder distention in WT mice.  These results indicate that mGluR5 has an 
important role in the modulation of distention-induced (non-inflammatory) bladder pain.  
Furthermore, these results support the previous finding that a less-specific antagonist of mGluR5 
is analgesic in distention-induced bladder pain (Hu et al., 2009).  We then used an infectious 
inflammatory model (UPEC) of bladder injury to investigate if mGluR5 has a role in inflammatory 
bladder pain.  We measured the VMR in mice with an UPEC-induced urinary tract infection, and 
then measured the VMR again following acute systemic treatment of with a specific mGluR5 
antagonist (fenobam).  UPEC-infected mice treated with fenobam has a reduced VMR when 
compared to the first round of bladder distention, suggesting that fenobam is analgesic. These 
data presented in chapter 3 suggest that mGluR5 is necessary for the full expression of 
inflammatory and non-inflammatory bladder pain.   
	   125	  
To determine if mGluR5 modulates micturition reflexes, we examined the urodynamic profile of 
mGluR5 KO mice compared to WT mice. The intermicturition interval is the rate at which the 
mouse voids while the bladder is being filled at a constant rate and an increased IMI indicates 
that the mouse allows the bladder to fill longer before voiding. mGluR5 KO mice had a 
significantly increased intermicturition interval (IMI) when compared to their WT littermates. 
Furthermore, acute systemic administration of the mGluR5 antagonist fenobam significantly 
increased the IMI in WT mice.  To continue this line of investigation, we would examine the IMI in 
mice with and without a UPEC bladder infection.  Since bladder infection is known to increase the 
voiding frequency in humans (Foxman, 2010) we could examine cystometry in mice with and 
without UPEC-induced infection to determine if a urinary tract infection results in an increased 
voiding frequency.  If UPEC infection increased voiding frequency and fenobam reduced the IMI 
in mice infected with UPEC, this may indicate that fenobam would be useful for treating 
overactive bladder.  The data presented in chapter 3 suggests that fenobam may be a useful drug 
for the treatment of bladder pain and overactive bladder.   
Together the results from chapter 3 support the hypothesis that mGluR5 has an important role in 
modulation of both inflammatory and non-inflammatory bladder pain.  Previous work using an in-
vitro bladder-nerve preparation demonstrated that an mGluR5 antagonist had no effect on 
distention-induced pelvic nerve firing (Hu et al., 2009).  These results suggest that mGluR5 in the 
bladder proper is not the site of modulation of bladder pain (Hu et al., 2009).  In addition, our 
preliminary rtPCR results of bladder mRNA suggesting that mGluR5 is not expressed in the 
bladder.  Taken together, these data imply that mGluR5 in the CNS may be important for the 
modulation of bladder pain. We hypothesized, in chapter 4, that mGluR5 in the central nucleus of 
the amygdala (CeA) modulates distention-induced bladder pain.   
mGluR5 in the CeA Modulates Distention-Induced Bladder Pain 
 mGluR5 has a pro-nociceptive role at multiple levels of the pain neuroaxis (Bhave et al., 
2001; Walker et al., 2001; Neugebauer and Carlton, 2002; Neugebauer and Li, 2002; Varney and 
Gereau, 2002; Kolber et al., 2010).  Recent work has demonstrated that mGluR5 in the central 
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nucleus of the right amygdala is important in the modulation of somatic inflammatory pain (Ji and 
Neugebauer, 2009; Kolber et al., 2010).  In addition, recent work has implicated the CeA in 
visceral pain (Ji and Neugebauer, 2009, 2010; Li et al., 2011).  In chapter 4 of this thesis, we 
hypothesized that mGluR5 in the CeA modulates bladder pain.  Pharmacologic inhibition and 
genetic deletion of mGluR5 in the right CeA was analgesic in the distention-induced bladder pain 
model, supporting our hypothesis.  However, we were surprised that inhibition of CeA mGluR5 
reduced the VMR in naïve (uninjured) mice. Previous work has demonstrated that inhibition of 
mGluR5 in the CeA is only analgesic in the presence of an injury (Kolber et al., 2010; Li et al., 
2011).  Although multiple rounds of bladder distention results in urothelial injury, we have not 
observed an increased VMR when compared to baseline responses.  We hypothesized that the 
injury to the bladder due to multiple rounds of distention may be allowing antagonism of mGluR5 
in the CeA to have analgesic effects.  We tested this hypothesis by injecting MPEP, an mGluR5 
antagonist, into the CeA prior to bladder distention.  We found that mice pretreated with MPEP 
had a reduced VMR when compared to mice pretreated with vehicle alone (figure 4.2).  These 
data suggest that mGluR5 modulates bladder pain in the absence of injury, which is a novel 
finding.  The apparent difference between these data and previously published work may 
highlight a distinction in the modulation of visceral and somatic pain or it may represent 
differences in the sensitivity of the pain tests used.  Any difference in sensitivity may be 
attributable to the fact that the VMR measures an evoked response to bladder distention, while 
previous work measured the mechanical threshold necessary to induce a withdrawal response or 
ultrasonic vocalizations in response to knee-joint compression or colon distention.  A second 
explanation for this apparent difference may be that mGluR5 modulation of bladder pain may be 
different than mGluR5 modulation of distention-induced colon pain.  In support of this, previous 
work has demonstrated that mGluR5 has a direct effect on the firing rate of peripheral nerves in 
the colon and not the bladder (Hu et al., 2009).    
To further support the hypothesis that mGluR5 in the CeA is necessary for the full expression of 
bladder pain, we examined how activation of mGluR5 would affect the VMR.  We 
pharmacologically activated group I mGluRs (mGluR5 and mGluR5) in the right CeA, and found 
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that this increased the VMR to bladder distention.  Activation of mGluR5 in the CeA increased the 
VMR, while inhibition or conditional deletion of mGluR5 in the CeA lead to a decrease in the 
VMR.  Together, these data support the hypothesis that mGluR5 in the right CeA is necessary for 
the full expression of distention-induced bladder pain.  Furthermore, these data suggest that 
activation of mGluR5 in the right CeA is sufficient to increase sensitivity to bladder distention.  We 
only examined the role of mGluR5 in the right CeA because of previous work demonstrating right 
hemispheric lateralization of pain modulation (Carrasquillo and Gereau, 2008; Ji and 
Neugebauer, 2009), and specifically of mGluR5 modulation of amygdala nociceptive processing 
(Kolber et al., 2010).  However, it is unknown if mGluR5 in the left amygdala has an important 
role in modulating bladder pain. Future work could examine if pharmacologic or genetic inhibition 
of mGluR5 in the left CeA is sufficient to reduce the VMR to bladder distention.  If inhibition of 
mGluR5 in the left CeA resulted in a similar reduction in the VMR to bladder distention, this may 
suggest that the processing/modulation of bladder pain does not undergo hemispheric 
lateralization.  Interestingly, a recent publication found no lateralization in corticosterone-induced 
visceral hypersensitivity to colorectal distention (Tran and Greenwood-Van Meerveld, 2012). 
Our results suggest that activation of mGluR5 in the right CeA is sufficient to increase the evoked 
response to bladder distention.  However, it is unknown how mGluR5 CeA activation leads to 
changes the spinal-evoked bladder pain reflex.  Possible mechanisms include increasing synaptic 
transmission or increased neuronal excitability.  We hypothesized that mGluR5 activation may 
lead to increased excitability of CeA neurons and thus an increase in output from the CeA. To test 
this hypothesis, we optogenetically activated the right CeA and examined its effect on the VMR.  
We found that an increase in CeA activity leads to an increased VMR in response to bladder 
distention.  These data support the hypothesis that activation of mGluR5 in the CeA modulates 
the VMR through increased activity of CeA neurons.   
In addition to a role for CeA mGluR5 in the modulation of bladder pain, we hypothesized that 
activation of mGluR5 in the CeA leads to descending modulation of neurons in the spinal cord.  
Previous work has demonstrated that chronic corticosterone implants in the CeA lead to both an 
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increased VMR to noxious bladder distention and increased excitability of visceral afferent 
neurons in the spinal cord (Qin et al.; Myers and Greenwood-Van Meerveld).  Furthermore, 
recent work by our lab found ERK activation in the lumbosacral spinal cord following noxious 
bladder distention (Lai et al., 2011). Furthermore, inhibition of ERK activation at the level of the 
spinal cord was analgesic in both inflammatory (cyclophosphamide-induced) and non-
inflammatory distention-induced bladder pain (Lai et al., 2011).  However, it was unknown if 
mGluR5 in the right CeA modulates activation ERK in the lumbosacral spinal cord. We found that 
noxious bladder distention results in ERK activation in the lumbosacral spinal cord, but not in the 
amygdala.  Mice lacking mGluR5 expression in the right CeA (mGluR5CKO) had less distention-
induced ERK activation in the spinal cord when compared to mice with normal mGluR5 
expression.  This suggests a relationship between descending activity from the CeA and 
distention-induced ERK activation.  We hypothesized if mGluR5 in the CeA modulates distention-
induced ERK activation in the spinal cord through increased CeA activity, then optogenetic 
activation of the CeA alone would not affect ERK activation in the lumbosacral spinal cord.  Our 
results support this hypothesis.  We found that optogenetic activation alone of the right CeA had 
no effect on ERK activation in the spinal cord, suggesting that increased CeA activity only 
modulates distention-induced ERK activation in the spinal cord. Future work could focus on 
understanding how mGluR5 in the amygdala modulates ERK activation in the spinal cord.  To 
confirm this link, we could activate mGluR5 in the CeA with and without noxious bladder 
distention and examine ERK activation in the spinal cord.  If activation of mGluR5 in the CeA 
coupled to noxious bladder distention resulted in higher levels of ERK activation in the spinal cord 
when compared to noxious bladder distention alone, this would support the hypothesis that 
mGluR5 in the CeA modulates distention-induced ERK activation in the spinal cord.  
The descending arm of the pain neuroaxis may follow the PAG to the RVM, and is connected to 
the spinal cord via the dorsolateral funiculus (DLF) (Basbaum et al., 1978; Basbaum and Fields, 
1979).  Descending modulation of visceral pain has been demonstrated to descend the spinal 
cord via the DLF (Zhuo and Gebhart; Gebhart). To determine if the CeA descending modulation 
of ERK activation travels through the DLF, we could lesion the DLF and examine how this lesion 
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affected CeA mGluR5 modulation of bladder pain. If a lesion of the DLF prevented CeA mGluR5 
modulation of ERK activation in the spinal cord, then this would support our hypothesis that 
mGluR5 in the CeA modulates distention-induced ERK activation in the spinal cord.  Additionally, 
we could lesion the DLF and assess whether inhibition or activation of mGluR5 in the CeA 
affected VMR responses.  If mGluR5 in the CeA modulates bladder pain by way of the DLF, then 
activation or inhibition of mGluR5 in the CeA would have no effect on the VMR in mice with a DLF 
lesion.  Future work could also examine which cell types in both the amygdala and spinal cord are 
involved in this pathway.  A first step in identifying the relevant cell types would be staining for 
cell-specific markers and the co-localization of mGluR5 in the CeA.  Additionally, we could look 
for co-localization of cell-specific markers and distention-induced phosphorylated (activated) ERK 
in the lumbosacral spinal cord.  This information would be helpful in determine which cell types 
may be important in regulating the downstream action of mGluR5.        
An additional area of future study could examine the secondary messengers downstream of 
mGluR5 in the CeA that have a role in the modulation of bladder pain.  Previous work has shown 
that mGluR5 activation couples through Gq/11, leading to activation of phospholipase C (PLC), 
phosphoinositide (PI) hydrolysis, and protein kinase C (PKC) activation (Gereau and Heinemann, 
1998; Ferguson et al., 2008).   However, recent work in the CeA demonstrated that reactive 
oxygen species (ROS) link mGluR5 to ERK and PKA through an IP3-dependent and PKC-
independent mechanism (Li et al., 2011).  We could determine if this PKC-independent pathway 
exists in bladder pain by determining if ROS scavengers block the increased VMR induced by an 
mGluR5 agonist.  We could also block PKA, PKC or IP3 in the CeA and see how they modulate 
the VMR.  To determine the downstream signaling from mGluR5 in the CeA that modulates ERK 
activation in the spinal cord, we could examine how intra-amygdala ROS scavengers, PKA or IP3 
inhibitors modulate distention-induced ERK activation in the spinal cord.  
Targeting mGluR5 to treat IC/PBS? 
The results of this thesis suggest that bladder pain is modulated at distinct anatomical levels.  
Furthermore, these data suggest that distention-induced bladder pain is modulated by mGluR5 
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activation.  The specific mGluR5 antagonist, fenobam, reduced the VMR to bladder distention in 
mice with and without bladder inflammation.  In addition, fenobam increased the IMI (see chapter 
3).  These results suggest that mGluR5 might be a good molecular target for treatment of IC/PBS 
or overactive bladder.  Furthermore, the results of chapter 4 strongly suggest that mGluR5 in the 
CeA has a key role in bladder pain modulation.  Inhibition of mGluR5 in the right CeA reduced the 
VMR to a similar extent as systemic administration of fenobam.  Overall, these data suggest that 
mGluR5, including activation in the CeA, is an important modulator of bladder pain.   
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